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SCOPE AND PLAN OF WORK 
 Herpes simplex virus (HSV) is a human DNA virus with two species, 
HSV-1 and HSV-2, that causes a variety of disease manifestations, the 
most common being localized recurrent skin and mucous vesicular 
lesions, occurring after primary infection (e.g., acute Herpetic 
Gingivostomatitis). Genital HSV is a sexually transmitted disease and 
there is strong evidence that it increases the risk of other infections 
through genital contact, in particularly HIV infection. Varicella-zoster virus 
(VZV) is a member of the herpes virus family. Primary infection is varicella 
(chickenpox), and its secondary infection is zoster (shingles). HSV2 
prevalence is increasing worldwide and HSV2 is the major cause of genital 
ulcer disease (GUD) in the developed world. In the developing world, the 
major public health importance of HSV2 lies in its potential role as a co-
factor for HIV transmission. WHO says that the HSV2 prevalence varies 
widely, with generally higher rates in developing than in developed 
countries and in urban than in rural areas. 
 WHO estimated that the HSV Prevalence is higher in the USA (22% 
in adults) compared with Europe (generally less than 15%). However, 
substantially higher rates are seen in Sub-Saharan Africa and the 
Caribbean, with prevalence in adults of around 50% in many countries. 
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Overall, prevalence is higher in women compared with men, especially 
among the young and rates of up to 40% have been recorded among 
women aged 15-19 in Kisumu, Kenya. HSV2 reactivation and duration of 
recurrences are significantly increased in HIV infected individuals. The 
frequency and severity of recurrences increases as CD4 cell count 
decreases. There is evidence that inclusion of Valacyclovir in antiretroviral 
therapy prolong survival in HIV seropositive individuals. One study has 
shown that HSV2 reactivation is associated with increases in plasma HIV1 
RNA and intracellular gag mRNA and that plasma HIV1 RNA level 
decreases significantly during treatment with Valacyclovir. As a result, it is 
possible that HIV progresses more rapidly in untreated HSV2 positive 
individuals. However, evidence is inconclusive and more studies of the 
effect of episodic HSV2 therapy on HIV are needed, especially in 
developing countries. Valacyclovir to be included for treatment of severe 
herpetic ulcers especially HIV infected individuals. Valacyclovir is an 
antiviral drug, which has been the standard treatment for genital herpes, 
varicella-zoster virus (VZV) for the past decade in developed countries. 
For primary infection in children, i.e., herpetic gingivostomatitis, small 
recurrent therapies (RCTs) suggest that oral Valacyclovir reduces the 
mean duration of pain and other symptoms. A few RCTs document that 
the frequency of recurrent herpes labials can be reduced by antiviral 
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therapy. Valacyclovir appears to be as effective as oral Acyclovir and 
somewhat better than Famcyclovir. Valacyclovir is available in generic 
forms, contrarily to other more recent antiherpetic drugs. In this context we 
planned to prepare Valacyclovir Nanoparticles formulation to increase the 
bioavailability of drug through targeting to the macrophage/monocyte 
systems of the body. Through this targeted drug delivery we can able to 
reduce the required drug dose for the therapy. This enables the reduction 
in the side effects and toxicity. 
(i)  To develop the nanoparticles formulation with antiviral drug 
Valacyclovir for enhanced macrophages and monocytes drug 
delivery and to have a controlled release effect. 
(ii) To enhance the bioavailability of Valacyclovir. 
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INTRODUCTION 
PARTICULATE CARRIERS 
          For almost 45 years researchers have attempted to use the 
properties of particulate colloidal systems for controlling the biological 
dispersion of drugs. Such carriers can be as small as 10nm in diameter 
and it may be monolithic or capsular. Types include lipid vesicles, protein 
microspheres, emulsion and natural or modified endogenous particles. 
         The perceived advantage of particulate colloidal carriers is that they 
can carry and protect an extremely high payload of drug while following 
their own biological pathways. However, particulate carriers are generally 
recognized by the body’s immune system and captured by the cells of the 
MPS; also, they cannot easily escape from the circulation, except where 
the endothelia are either discontinuous or damaged. 
         Particulate colloidal carriers have been considered for both 
intravascular targets. Much recent attention has been paid to adjusting the 
surface of such materials in an attempt to fool the immune system into 
treating these drug carriers as being non-foreign. Such stealth approaches 
will increase the probability that the carriers will be able to interact with 
features of the target site, or will persist as circulating depots of drug in the 
central blood compartment. 
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        Various factors affecting the release of drugs from particulate 
carriers are such as, 
Drug  
• Position in the particle 
• Molecular weight 
• Physicochemical properties 
• Drug-carrier interaction 
• Diffusion; desorption from surface  
Particles  
• Type and amount of matrix material  
• Size and density of the particle 
• Capsular or monolithic  
• Extent and nature of any cross-linking; denaturation of 
 polymerization  
• Presence of adjuvants 
• Surface erosion; particle diffusion and leaching  
• Total disintegration of particles 
Environment 
• Hydrogen ion concentration  
• Polarity        
• Ionic strength 
• Presence of enzymes 
• Temperature 
• Microwave 
• Magnetism 
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• Light (Vijayakumar, Gilbert.S.B., 2001) 
NANOPARTICLES 
 Controlled and targeted delivery is one of the most enviable 
requirements from a carrier, which involves multi-disciplinary site-specific 
or targeted approach. One attempt to achieve this goal was the 
development of colloidal drug carriers known as Nanoparticles. The 
concept of using nanoparticles as a vehicle for drug delivery was first 
developed by Speiser and co-workers in the late 1960s and early 1970s. 
Nanoparticles are solid colloidal particles ranging in size from 10 to 1000 
nm (1micrometer). In which the active principle (drug or biologically active 
material) is dissolved, entrapped, and/or to which the active principle is 
adsorbed or attached. Nanoparticulate drug delivery system may offer 
plenty of advantages over conventional dosage forms, which include 
improved efficacy, reduced toxicity, enhanced biodistribution and improved 
patient compliance. 
DRUG RELEASE  
 The drug release from nanoparticles can be occurred by different 
methods. 
• Desorption of surface bound drug  
• Diffusion through the nanoparticle matrix 
• Diffusion through the polymer wall 
• Nanoparticle matrix erosion 
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• A combined erosion diffusion process. 
POLYMERS EMPLOYED AS NANOPARTICLES 
Synthetic polymers: 
•   Poly methyl methacrylate 
  • Poly methyl methacrylate copolymers 
  • Poly methyl cyanoacrylate 
  • Poly isobutyl cyanoacrylate 
  • Poly hexyl cyanoacrylate 
  • Ethyl cellulose 
  • Eudragit RL 
  • Eudragit RS 
Natural polymers: 
• Serum albumin 
•  Gelatin 
• Lecithin 
• Collagen 
• Casein  
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Types of Nanoparticles used as carrier for therapeutic and  
diagnostic agents 
 
S. No. Types of Nanoparticles Materials used Applications 
1 Polymeric Nanoparticles Biodegradable polymers 
Controlled and targeted 
drug delivery 
2 Solid lipid Nanoparticles 
Melted lipid dispersion 
in an aqueous 
surfactant 
Least toxic and more stable 
colloidal carrier systems as 
alternative materials to 
polymers 
3 Nanosuspensions and Nanocrystals 
Drug powder is 
dispersed in a 
surfactant solution. 
Stable system for 
controlled delivery of water-
insoluble drugs 
4 Polymeric micelles Amphiphilic block copolymer 
Systemic and controlled 
delivery of poorly soluble 
drugs 
5 Ceramic Nanoparticles Silica, Alumina, Titania 
Drug targeting,            
Bio-molecules delivery 
controlled and targeted 
drug delivery carriers for 
site specific drug delivery 
6 Liposomes Phospholipid vesicles Controlled and targeted drug delivery 
7 Dendrimers Biodegradable polymers 
Carriers for site specific 
drug delivery 
8 Magnetic Nanoparticles 
An inorganic core of 
iron oxide coated with 
polymer 
Drug targeting , diagnostic 
tool in biology and 
medicine 
9 Nanoshells coated with gold Dielectric core and a metal shell. Tumor targeting 
10 Nanowires or Carbon Nanotubes 
Metals, 
semiconductors or 
carbon Aerogel 
Gene and DNA delivery 
11 Nanopores Aerogel Controlled release drug carriers 
12 Quantum dots CdSe-CdS core-shell Targeting, Imaging agents 
13 Ferrofluids 
Iron oxide magnetic 
nanoparticles 
surrounded by a 
polymeric layer 
For capturing cells 
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Polymers used in nanoparticle formulations 
 Common classes of polymers used to encapsulate drugs in colloidal 
systems include polyamides, poly (amino acids), polyesters, poly- 
orthoesters and poly anhydrides. 
Polyesters 
 Recently, biodegradable polyesters such as poly (lactic acid), poly 
(glycolic acid) and the copolymers of lactic and glycolic acid, i.e.,poly 
(lactide-co-glycolide). (PLGA) have been used extensively for biomedical 
applications. Being biodegradable they have the advantage of not 
requiring surgery for removal after they have served their purposes. They 
protect the entrapped drug against degradation and control its site specific 
delivery. They are synthesised through ring opening polymerisation of 
cyclic lactones. These copolymers (with varying lactide: glycolide ratios) 
are amorphous and easily dissolve in organic solvents such as 
dichloromethane and ethyl acetate. The degradation rate in water is a 
function of the molecular weight and the lactide:glycolide ratio. Higher 
glycolide content and lower molecular weight increase the degradation 
rate. As they are all strongly hydrophobic they are more efficient for 
encapsulation of hydrophobic drugs than hydrophilic drugs. A burst 
release is another characteristic observed with nanoparticles made from 
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PLGA. The drug release from PLGA microparticles often has a tri-phasic 
pattern in vitro as well as in vivo. A fast initial release phase (burst) 
followed by a second slow release phase lasting days or weeks and a third 
rapid release phase is seen in particular with peptide and protein drugs. 
The burst release is undesirable in most of the sustained-drug delivery 
applications, since the dosage of the potent drug encapsulated is required 
to be released over a long period of time. Even a small percentage of the 
drug immediately released would increase its local concentration to an 
extent near or above that at which the drug becomes toxic in vivo. The 
defence mechanism of the body would respond to this increased toxicity 
level by forming additional layers of tissues on the polymer surface, 
thereby disrupting the entire release profile and mechanism. Any drug 
released during the burst stage may be metabolized and excreted without 
being effectively utilized as it may not reach its target tissue. Except for 
vaccines, a tri-phasic drug release is generally not desirable for most drug 
therapies. Insufficient drug may be delivered to maintain the desired 
pharmacological effect in the slow release phase and toxicity problems 
may occur during the rapid initial and third release phases because of too 
high drug levels. The fast initial release (burst) is commonly attributed to 
drug localised on the surface of particles or to easily accessible drug, for 
example, in the case of highly porous microparticles. Thereafter, a 
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diffusion-controlled slower release phase follows. Finally, when the 
molecular weight of PLGA approaches a certain lower threshold, the 
weight of the microparticles decreases rapidly and an erosion-controlled 
rapid release phase occurs. Recently, the formation of a nonporous film 
around the microparticles after incubation in the release medium has been 
reported. The decreased surface porosity of the microparticles led to 
reduced drug permeability and resulted in the slow release phase without 
burst release. 
Poly (Ethylene glycol) based block co polymers 
 The nature of the surface of the nanoparticles largely influences 
their biodistribution following in vivo administration. Hydrophobic 
nanoparticles are rapidly cleared from the systemic circulation by the MPS, 
ending in the liver or in the spleen. The hydrophobic nature of most 
biodegradable particles could limit the applicability of these carriers in 
many drug delivery applications. In order to overcome concerns of 
clearance by the MPS, surface modification techniques have been utilized. 
These modification techniques ultimately produce a particle that is not 
recognized by the MPS by rendering the surface of the particle hydrophilic. 
Several types of surface modified nanoparticles have been described in 
recent literature. The most common moiety used for surface modification is 
poly (ethylene glycol) (PEG). PEG is a hydrophilic, non-ionic polymer that 
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has been shown to exhibit excellent biocompatibility.  
PEG molecules can be added to the particles via covalent bonding or by 
surface adsorption. The presence of a PEG brush on the surface of 
nanoparticles besides increasing residence time in the systemic circulation 
can also reduce protein and enzyme adsorption on the surface and thus 
can retard particle degradation. The degree of protein adsorption can be 
minimized by altering the density and molecular weight of PEG on the 
surface. The stability of PLA particles has been shown to increase in 
simulated gastric fluid (SGF) with the addition of PEG on the particle 
surface. After 4 hours in Simulated Gastric Fluid, 9% of the PLA 
nanoparticles converted to lactate versus 3% conversion for PEG-PLA 
particles. PEG is also believed to facilitate transport through the Payer’s 
patches of the Gut-associated lymphoreticular tissue. Usually PEG block 
co-polymers show quite different properties compared to the constituent 
polymers lactic acid and glycolic acid. PLGA – PEG block co-polymers are 
hence used as biomaterials with their own unique properties and classified 
as triblock, star block, branched or graft block co-polymers as illustrated in 
Fig. 1. 
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Fig. 1. Schematic representation of (a) Monblock (b) Diblock  
(c )Triblock (d) Multiblock (e) Multiblock branched or comb  
(f) Star shaped. 
 
 PLGA degradation shows autocatalysis wherein bulk degradation 
occurs with a decrease in pH resulting from the release of lactic acid and 
glycolic acid monomers. The resulting carboxyl groups, oligomeric PLGA 
can increase degradation of the PLGA formulation. Block co-polymers with 
PEG have also gained attention as an alternative for overcoming these 
side effects. Another main drawback of these polymers is their non specific 
interaction with cells and plasma proteins, leading to accumulation in    
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non target cells causing limitations in practical drug formulations. Hence, 
surface modified nanoparticles have been developed to control their 
interactions. PEG coated (sterically stabilised) nanoparticles can avoid 
sequestration by the Mononucleur Phagocyte system (MPS) and hence 
show increased circulation time in the body. However, these coated 
nanoparticles lack functional groups for ligand coupling. Some successful 
attempts have been reported for PEG systems where a terminal functional 
group has been added to PEG. Polysaccharide coatings have also been 
studied since they are alternative hydrophilic molecules. Some 
polysaccharides facilitate mucoadhesion or function as recognition factors 
allowing recognition. For example PEG Dextran or Dextran PLA. 
Biodegradable and biocompatible polymers such as poly (lactide) (PLA), 
poly (ε-caprolactone) (PCL), poly (β-benzyl L-aspartate) (PLBA), and poly 
(γ-benzyl L-glutamate) (PLBG) have been commonly used for the core 
material of micelles while PEO and PEG are used as hydrophilic blocks. 
Studies on polymeric micelles comprised of PEO as hydrophilic block and 
PCL, PLA, PLBA, PLBG as hydrophobic block have been carried out by 
many groups. Amphiphilic block copolymers have the ability to produce 
nanoparticles by self assembling in an aqueous environment. The 
hydrophobic blocks of the copolymer form the core of the micelle, while the 
hydrophilic blocks form the corona or outer shell. The solubility of the 
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hydrophobic drug in the aqueous media is greatly increased by the use of 
micelles.  Thus, incorporating a drug in the micelle is an effective method 
of preparing an efficient drug delivery system. 
Poly caprolactones (PCL) 
 Poly (ε-caprolactone) (PCL) obtained by ring opening 
polymerization of  ε-caprolactone was first reported by Pitt et al.,(1990) for 
the controlled release of steroids and narcotic antagonists as well as to 
deliver ophthalmic agents. PCL, aliphatic polyester has been intensively 
investigated as a biomedical material. It demonstrates a low melting point 
(57°C) and a low glass-transition temperature (−62°C). Under 
physiological conditions, PCL can be degraded by microorganisms as well 
as by hydrolysis. Under certain circumstances, it is possible to 
enzymatically degrade cross linked PCL (termed enzymatic surface 
erosion). Low molecular-weight fragments of PCL are also reportedly 
absorbed by macrophages intracellularly. The rate of biodegradation for 
PCL is slower than other biodegradable materials thus making it suitable 
for design of long term implantable systems. For example, Capronor, a US 
FDA approved contraceptive device. Another interesting property of PCL is 
its propensity to form compatible blends with a wide variety of polymers. 
Molpeceres et al.,(1999) studied cyclosporine encapsulation within 
Polycaprolactone nanoparticles and reported 95% encapsulation efficiency 
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within the particles. They also showed that this formulation offered a good 
alternative to existing cyclosporine formulations as far as drug monitoring 
is concerned. Synthesis of amphiphilic copolymer based on Dextran 
grafted with PCL chains which significantly reduced protein absorption. 
Recently, Merle and coworkers reported encapsulation of vancomycin in 
biodegradable PCL microparticles for bone implantation. 
Poly (alkylcyanoacrylates) 
 Poly (alkylcyanoacrylates) has been used as tissue adhesives in 
surgery since these are well tolerated in vivo. Unlike PLA and PGA, here 
only the side chains are biodegradable and not the backbone. Their 
delayed degradation characteristics thus do not generate an acidic 
environment during drug release. This has prompted intense research for 
their use in many nanoparticles formulations. The production of NPs by 
mechanically polymerizing the dispersed methyl or ethyl cyanoacrylate in 
aqueous acidic medium without irradation or an initiator in the presence of 
polysorbate-20 as a surfactant. Busulfan entrapment by nanoprecipitation 
into five different types of poly (alky cyanoacrylate) polymers. The 
polymers leading to the highest busulfan loading efficiencies were 
poly(isobutyl  cyanoacrylate) (PIBCA) and poly (ethyl cyanoacrylate) 
nanoparticles displaying busulfan loading ratios equal to 5.9% (w/w) 
together with nanoparticle yields of 71% (w/w). The in vitro release studies 
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under sink conditions, in water, or in rat plasma showed a fast release in 
the first 10 min followed by a slower one over 6 h.  
 The potential of poly (alkylcyanoacrylate) (PACA) NPs to overcome 
multidrug resistance problems at cellular level and in relation to drug 
biodistribution. Resistant cells treated with doxorubicin loaded poly 
(alkylcyanoacrylate) nanoparticles showed a much higher sensitivity to the 
drug, relative to the free drug when compared with NPs using other 
biodegradable polymers. The mechanism proposed to explain the ability of 
doxorubicin-loaded PACA nanoparticles to overcome the resistance to 
doxorubicin in resistant cancer cells was based on the adhesion of the 
nanoparticles to the cell surface, followed by the simultaneous release of 
the drug and nanoparticles degradation product (poly cyanoacrylic acid) 
that combine as an ion-pair able to cross the cell membrane without being 
recognized by the Poly glycoprotein. To date, only the poly (alkyl 
cyanoacrylate) nanoparticles have been identified as to be fulfilling these 
requirements to overcome the resistance caused by the P- glycoprotein 
complex. Lipid nanocapsules prepared using poly (alkyl cyanoacrylates) 
were between 25 to 100 nm in size and showed fast initial release of 60 to 
75% in the first 48 hours. However the major limitations associated with 
use of this polymer are the particle size, high cell uptake and toxicity. 
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Poly (ortho-esters) (POE) 
 Poly (ortho-esters) is another important group of hydrophobic 
polymer with drug delivery applications and are synthesised by the 
addition of polyols to diketene acetals. POEs possess acid sensitive ortho-
ester linkages that undergo rapid hydrolysis at physiological pH and an 
even faster rate in an acidic pH. Therefore, incorporation of a small 
amount of acidic excipients may help to control the hydrolysis rate. On the 
other hand, incorporation of basic excipients stabilises the bulk of the 
matrix but facilitates erosion at the surface. The polymers conjugated with 
N- hydroxysuccimide were hydrolyzed in a biphasic mode, with a fast initial 
phase occurring in the first few hours, followed by a slower phase in the 
next few days. These ionomers represent a novel class of biomaterials 
with readily controllable physical and chemical attributes for tissue 
engineering. 
Polyanhydrides (PA) 
 Polyanhydrides are hydrophobic and contain water sensitive 
linkages that may undergo hydrolytic bond cleavage to generate water-
soluble degradation products. Surface erosion takes place due to water 
sensitive linkages. The majority of Polyanhydrides studied are based on 
Sebacic acid (SA), P- (carboxyphenoxy) propane (CPP) and  
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P-(carboxyphenoxy) hexane (CPH). The Sebacic acid component of 
biodegradable PAs is utilised as a surface eroding drug delivery device.   
A wide variety of drug and proteins have been incorporated into PAs and 
their modified forms e.g. poly (anhydride-esters), poly (anhydride-imides), 
etc. and their potential release characteristics have been evaluated. 
Polyamides 
 Polyamides form another important class of polymers particularly as 
drug delivery matrices. Polyamides with a structural resemblance to 
polypeptides are used as matrices for the transport of drugs. Examples 
include different types of poly (amino acids) such as poly (L-glutamic acid), 
poly (aspartic acid) are derived from the corresponding natural amino 
acids. Nakanishi and co-workers have developed a polymeric micelle 
carrier system consisting of PEG-conjugated doxorubicin: poly (aspartic 
acid) for the transport of doxorubicin. This carrier system has a highly 
hydrophobic inner core, and therefore, it can also entrap a useful amount 
of doxorubicin in addition to the conjugated doxorubicin. It circulated in the 
blood for a long-time and evaded RES uptake due to the hydrophilic 
polyethylene glycol outer layer. It was effectively accumulated in the 
tumour tissue by the EPR effect. The entrapped Doxorubicin was released 
from the inner core by diffusion and expressed stronger activity than free 
Doxorubicin against all the tumour lines tested. Li and co-workers have 
synthesised a novel biodegradable poly (ester amide) derived from          
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3-morpholine and ε-caprolactone. Increase in morpholine content 
enhanced water absorption of the polymers in vitro degradation data and 
release profiles of 5-fluorouracil showed that both the degradation rate and 
drug release rate increased with an enhanced morpholine content in the 
polymers. 
Preparation Techniques 
 Preparation of nanoparticles can be a variety of different ways. The 
most important and frequently used is emulsion polymerization, solvent 
evaporation nanoprecipitation, salting out, and desolvation of natural 
proteins. 
            The materials used to prepare nanoparticles are also numerous, 
but most commonly they are polymers such as poly alkylcyanoacrylates, 
poly methylmethacrylate, polybutyl cyanoacrylate or from albumin. 
 For drug loading of nanoparticles, three major strategies can be 
employed:  
(i) Covalent attachment of the drug to the particle surface or to the 
 polymer prior to preparation.  
(ii) Adsorption of the drug to a preformed carrier system. 
(iii)  Incorporation of the drug into the particle matrix during particle 
 preparation.  
 The release rates of nanoparticles depend upon: 
(i) Desorption of the surface- bound/adsorbed drug.  
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(ii) Diffusion through the nanoparticle matrix. 
(iii) Diffusion (in case of nanocapsules) through the polymer wall.  
(iv) Nanoparticle matrix erosion.  
(v) A combined erosion/diffusion process.  
 During these preparation and release processes, the bioactivity of 
therapeutic agent must remain intact. Therefore, the ideal goal would be to 
achieve satisfactory protein stabilization and appropriate release through a 
reasonable preparation strategy.  
Depending on the method of preparation, nanoparticles, 
nanospheres or nanocapsules can be obtained with different properties 
and release characteristics for the nanocapsulated therapeutic agent. 
Nanocapsules are vesicular systems in which the drug is confined to a 
cavity surrounded by a polymer membrane, whereas nanospheres are 
matrix systems in which the drug is physically and uniformly dispersed 
(See Fig. 2) 
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Fig. 2. Schematics of exemplary types of drug nanoparticles. 
A.  Matrix type nanosphere, drug molecules are evenly dispersed in the 
polymer matrix.  
B.  Core shell nanocapsule, drug molecule is presented in a core 
covered with a polymer shell.  
C.  Matrix type nanosphere where drug crystals are embedded in a 
 polymer matrix. 
1.  Solvent displacement  
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          Solvent displacement or nanoprecipitation, also known as the 
Marangoni effect, has become a popular technique to prepare 
nanoparticles due to narrow size distribution, absence of shear stress, 
and absence of surfactants for amphiphilic polymers. This method differs 
from the emulsification diffusion and salting-out methods in that formally 
no precursor emulsion is formed during nanoparticle preparation. 
Basically, nanoparticle formation can be explained in terms of the 
interfacial turbulence and the “diffusion-stranding” processes between 
two unequilibrated liquid phases shown in Figure 3. When both phases 
are in contact, it is assumed that solvent diffuses from the organic phase 
into the water and carries with it some polymer chains which are still in 
solution. During the solvent diffuses further into the water, the 
associated polymer chains aggregate and form nanoparticle shown in 
Figure 4. The mechanism of nanoparticle formation can be described 
based on the water-solvent, water-polymer and solvent-polymer 
interactions. With this technique, PLGA, PCL, SB-PVA-g-PLGA and 
Methacrylic acid copolymer nanoparticles loaded with therapeutic drugs, 
e.g. TRH and elcatonin, cyclosporin A were extensively studied. 
However, the exposure to organic solvent for labile proteins during the 
preparation process and low encapsulation efficiency for water soluble 
drugs limit the application of this method.  
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Fig. 3. Schematic diagram of the mechanism of Marangoni effect 
 
 
Fig. 4. Schematic diagram of nanoparticles preparation using solvent 
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displacement method 
 
2.  Adsorption process 
 Stabilization of proteins in delivery devices and design of 
appropriate protein carriers are major research issues. Preservation of 
bioactive protein and improvement of drug loading during nanoparticles 
preparation based on defined colloidal characteristics are a great 
challenge. Denaturation of protein during preparation primarily is due to 
high shear forces and solvent exposure; furthermore, high acidity in the 
nanoparticles matrix due to the polymer degradation also leads to the loss 
of bioactivity of protein.  
 Compared to other loading methods, this adsorption technique can 
be performed in an aqueous solution and at a low temperature, improving 
the prospects for preserved activity of sensitive drug molecules. Moreover, 
polymer degradation has no detrimental effect on the protein absorbed on 
the surface of nanoparticles. However, it is reported that a large amount of 
drug can be entrapped by the incorporation method when compared to the 
adsorption. For a successful NP system, a high loading capacity is 
desirable to reduce the quantity of the carrier required for administration. 
Many efforts have been made to develop a method to associate the 
protein to the nanoparticle surface by adsorption. Additionally, a higher 
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burst release up to 60-70% for the NPs loaded with drug by adsorption. 
Further efforts related to adsorption process need to be made to 
investigate the interaction between the protein molecules and surface of 
NPs, to improve the loading efficiency and to achieve the desired release 
profile.  
3.  Surface adsorption on preformed particles with ionic surface 
 charge 
 An elegant and efficient method for protein loading was done by 
surface adsorption of bioactive materials onto unloaded PLGA particles 
carrying a surface charge. One may take advantage of the protein's 
surface charge, which depends on its pI and the pH of the medium in 
which it is dispersed. PLGA or any other type of particles can be readily 
decorated with positive or negative surface charges by simply preparing 
the particles by W1/O/W2 solvent evaporation/extraction process where the 
W2 phase contains a cationic emulsion stabilizer [hexadecyltrimethyl- 
ammonium romide; poly (ethyleneimine); stearlyamine] or an anionic 
emulsifier (sodium dioctyl-sulfosuccintate; sodium dodecylsulfate).  
 Such compounds attach tightly to PLGA surfaces during 
preparation and provide the necessary surface charge for ionic adsorption 
of counter-ions. In these systems, however, the use of chlorinated solvents 
and high amounts of surfactants, detergents during particle preparation 
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may affect their biocompatibility, in particular for the development of 
injectable formulations. A recent approach has been employed using 
biodegradable polymers carrying cationic or anionic groups, such as 
sulfobutylated copolymers. Particles made from such polyelectrolytes 
exposed surface charges, which were used to adsorb oppositely charged 
protein antigens. Provided that the ionic interaction between the particle 
surface and the adsorbate does not hamper the activity and availability of 
the bioactive material, such systems should hold great promise for antigen 
and DNA delivery. The use of particles with ionic surface charge offers 
several advantages over classical micro- or nano-encapsulation, amongst 
which the mild conditions for loading is probably the most attractive. PLGA 
particles with surface adsorbed protein antigens and DNA have been 
highly efficient in inducing strong immune responses, as recently reviewed 
by Singh et al., (2000). 
  
Methods for the characterization of Nanoparticles 
Parameters Methods 
Particle size 
Scanning electron microscopy (SEM) 
Transmission electron microscopy 
(TEM) 
Molecular weight Gel chromatography 
Density Helium compression pycnometry 
Crystallinity X- ray diffraction 
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Surface charge Electrophoresis Laser Doppler anemometry 
Hydrophobicity Hydrophobic interaction chromatography 
Surface element analysis X- ray photoelectron spectroscopy for chemical analysis (ESCA) 
In vitro release 
Biological membranes, Dialysis bag 
diffusion, Ultra centrifugation, Ultra 
filtration. 
Nanoviricide approach for destruction of viruses: 
 Research on antiviral nanoparticles has provided clues to the 
regulation of cytoplasmic transport. Viruses that replicate their genomes in 
the nucleus make use of the microtubule and the cytoskeleton as 
molecular motors for trafficking toward the nuclear membrane during entry 
and the periphery during egress after replication. Analyzing the underlying 
principles of viral cytosolic transport will be helpful in the design of viral 
vectors to be used in research as well as human gene therapy, and in the 
identification of new antiviral target molecules (Dohner and Sodeik., 2005). 
Reason for drug delivery of antiviral drugs: 
 Antiviral drugs are designed with the aim to act on virus-specific 
processes differing from normal biological events in the host cells. 
Nevertheless, complete virus specificity is never obtained and 
manipulation of the whole body disposition may be necessary to obtain a 
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sufficient therapeutic index. 
Features prompting the design of drug targeting formulations for 
antiviral compounds are:  
• Extremely rapid excretion or metabolism, endangering the formation 
of therapeutic concentrations at practical dosage regimens. 
• Severe toxicity in non-target tissue. Examples are bone marrow 
depression and severe neurotoxicity of Vidarabine (Ara-A) or 
formation of very toxic metabolites as recently reported for 
Zidovudine (AZT). 
• Poor penetration into the target cells, e.g. Anionic agents that are 
potent reverse transcriptase inhibitors and anti-herpes drugs that 
poorly penetrates the Blood Brain Barrier (BBB). 
• Inadequate phosphorylation of nucleoside analogues into their 
active triphosphate forms. 
• Poor water solubility leading to limitation in topical administration or 
precipitation of the drug in the renal tubuli Acyclovir (ACV). 
Controlled delivery of Nanoviricide 
Controlled delivery of drug is also important.  It provides  
•  Controlled, including linear, release profile. 
•  Low initial release: no burst. 
•  Well- preserved compound stability and activity. 
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• Biodegradable and biocompatible. 
Targeted delivery of Nanoviricide 
  Targeting drugs to specific organs, tissues, or cells is an attractive 
strategy for enhancing drug efficacy and reducing side effects. Drug 
carriers such as antibodies, natural and manmade polymers, and labeled 
liposomes are capable of targeting drugs to extracvascular sites.  An 
alternative strategy is to use low molecular weight prodrugs that distribute 
throughout the body but cleave intracellularly to the active drug by an 
organ-specific enzyme.  
 
Fig. 5.   Principle of drug targeting by carriers 
 An example of this approach is a series of phosphate and 
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phosphonate prod rugs, called Hep Direct prod rugs, which enable liver-
targeted drug delivery following a cytochrome P450-catalyzed oxidative 
cleavage reaction inside hepatocytes (Erion et al., 2005) .Glutathione 
within the hepatocytes rapidly, reacted with the byproduct to form a 
glutathione conjugate. No byproduct-related toxicity has been observed in 
hepatocytes or animals treated with HepDirect prodrugs. HepDirect 
prodrugs represent a potential strategy for targeting drugs to the liver and 
achieving more effective therapies against chronic liver diseases such as 
hepatitis B and C.  
 
NANOPARTICLES AS A CARRIER FOR ANTIVIRAL DRUGS 
The carrier approach: 
 The antiviral drug is covalently coupled to soluble macromolecules 
or included in particle type of drug carrier nanoparticles. The fate of the 
drug in the body is now dictated by the chosen carrier. The drug 
concentration in the target tissue is a resultant of relative rates of cellular 
uptake of the drug conjugate, liberation of the drug as well as efflux rate of 
free drug from the target tissue. The advantage of targeting is only 
significant if the target compartment is different from the compartment 
where toxicity is occurring and if the active drug is released predominantly 
at the target site. 
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The Prodrug approach: 
  Chemical derivatives of the drugs are prepared those has more 
favourable kinetic features and/or are specifically activated at the site of 
action. 
Preferably the release rate should be controllable 
 Nanocarriers have important potential applications for the 
administration of therapeutic molecules. Nanoparticles made from 
polyhexylcyanoacrylate (PHCA) or human serum albumin (HSA) with a 
diameter of 200nm were found to be most suitable for targeting of antiviral 
substances to macrophages. (Hagen von Briesen et al., 1996). 
 Silver nanoparticles undergo a size-dependent interaction with viral 
and particles in the range of 1-10 nm attached to the virus  
(Elechiguerra et al., 2005). The regular spatial arrangement of the 
attached nanoparticles, the center-to-center distance between 
nanoparticles, and the fact that the exposed sulfur-bearing residues of the 
glycoprotein knobs would be attractive sites for nanoparticle interaction 
suggest that silver nanoparticles interact with the virus via preferential 
binding to the glycoprotein knobs. Due to this interaction, silver 
nanoparticles inhibit the virus from binding to host cells, as demonstrated 
in vitro. (Hagen von Briesen et al.,1996). 
APPLICATIONS AND ADVANTAGES OF DRUG CARRIER VEHICLE 
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 Polymeric nanoparticles made from natural and synthetic polymers 
have received the majority of attention due to higher stability and the 
opportunity for further surface nanoengineering. They can be tailor-made 
to achieve both controlled drug release and disease specific localization by 
tuning the polymer characteristics and surface chemistry. It has been 
established that nanocarriers can become concentrated preferentially in 
the tumour mass, inflammatory sites, and at infectious sites by virtue of the 
enhanced permeability and retention (EPR) effect of the vasculature. Once 
accumulated at the target site, hydrophobic biodegradable polymeric 
nanoparticles can act as a local drug depot depending upon the make-up 
of the carrier, thus providing a source for a continuous supply of 
encapsulated therapeutic compound at the disease site, such as, a solid 
tumour. These systems in general can be used to provide targeted 
(cellular/tissue) delivery of drugs, to improve oral bioavailability, to sustain 
drug/gene effect in the target tissue, to solubilize drugs for intravascular 
delivery, and to improve the stability of therapeutic agents against 
enzymatic degradation (nucleases and proteases), especially of protein, 
peptide, and nucleic acids drugs. Thus, the advantages of using 
nanoparticles for drug delivery result from two main basic properties viz. 
small size and use of biodegradable materials. Nanoparticles, because of 
their small size, can extravasate through the sites of viral inflammation and 
cancer cells or penetrate into smaller capillaries, cross the fenestration 
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present in the epithelial lining (e.g., liver), and are generally taken up 
efficiently by the cells which allow efficient drug accumulation at the target 
sites. Many studies have demonstrated that nanoparticles of sub-micron 
size have a number of advantages over microparticles as a drug delivery 
system. Nanoparticles have a further advantage over larger microparticles 
as they are better suited for intravenous (i.v.) delivery. The smallest 
capillaries in the body are 5–6 µm in diameter. The size of particles being 
distributed into the bloodstream must be significantly smaller than 5 µm, 
without forming aggregates to ensure that the particles do not form an 
embolism. In some cell lines, only submicron nanoparticles can be taken 
up but not large size microparticles. Generally nanoparticles have 
relatively higher intracellular uptake compared to microparticles and are 
available to a much wider range of biological targets due to their small size 
and relative mobility. The 100 nm nanoparticles had a 2.5 fold greater 
uptake than 1 µm microparticles, and 6 fold greater up take than 10 µm 
microparticles in a Caco-2 cell line. In a similar study, the nanoparticles 
penetrated throughout the submucosal layers in a rat in situ intestinal loop 
model, while microparticles were predominantly localized in the epithelial 
lining. Secondly, the use of biodegradable materials for nanoparticle 
preparation allows sustained drug release within the target site over a 
period of days or even weeks. Biodegradable nanoparticles formulated 
from poly D, L-lactide co-glycolide (PLGA) and Polylactide (PLA) have 
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been developed for intracellular sustained drug delivery, especially for 
drugs with an intracellular target. Rapid escape of PCL nanoparticles from 
the endo-lysosomal compartment to the cytoplasmic compartment has 
been demonstrated. Thus, nanoparticles could be an effective drug 
delivery mechanism for drugs whose targets are cytoplasmic. Greater and 
sustained antiproliferative activity was observed in vascular smooth 
muscle cells which were treated with dexamethasone-loaded 
nanoparticles compared to that seen with drug in solution. Nanoparticles 
were effective in sustaining intracellular dexamethasone levels, thus 
allowing a more efficient interaction with the glucocorticoid receptors which 
are cytoplasmic. 
HSV2 AND HIV 
HSV2 
 Herpes simplex virus type 2 (HSV2) infection is the primary cause 
of genital herpes. It is highly prevalent in human populations in many parts 
of the world, and is the most common cause of genital ulcer disease 
worldwide. In developing countries, the major public health importance of 
HSV2 relates to its potential role in facilitating HIV transmission. HSV2 is 
highly prevalent in most regions experiencing severe HIV epidemics, with 
infection rates rising steeply with age to reach levels of 70% or more 
among adult women and men in some African countries. Genital ulcer 
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disease enhances the infectiousness of HIV-positive subjects and the 
susceptibility of HIV-negative subjects, and clinical research has shown 
effects of HSV2 infection on genital HIV shedding. The reciprocal effect of 
HIV immune suppression on the exacerbation of HSV2 symptoms implies 
that there is a positive feedback loop, with HIV enhancing HSV2 
expression, which in turn may enhance HIV infectiousness and its spread. 
Accumulating data suggest that HSV2 may be responsible for a 
substantial proportion of new HIV infections in some parts of Africa. There 
is an urgent need to consider potential control measures for HSV2 that 
might be applied in an effort to curb HIV transmission. These might include 
episodic or suppressive antiviral therapy, for example among high-risk 
groups, and behavioral interventions designed to reduce herpes 
transmission. Candidate HSV2 vaccines and vaginal microbicides are also 
under development. An increasing proportion of genital ulcer cases in 
Africa are now attributable to HSV2, and the implications for treatment 
algorithms also need to be considered. Given the increasing awareness of 
the link between HSV2 and HIV, international technical workshops   
existing knowledge concerning the epidemiology and control of HSV2 in 
developing countries and its interaction with HIV. While the main focus 
was on developing countries, where the public health burden of HSV2 is 
greatest, experts from industrialized countries were also invited to share 
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perspectives from these countries, where much previous research has 
been conducted. 
EPIDEMIOLOGY AND NATURAL HISTORY OF HSV2 
Global epidemiology of HSV2 
HSV2 prevalence is increasing worldwide and the major cause of 
genital ulcer disease (GUD) in the developed world. In the developing 
world, the major public health importance of HSV2 lies in its potential role 
as a co-factor for HIV transmission. The high prevalence of HSV2 in many 
populations results from the fact that it is a lifelong infection, which is 
highly infectious and often transmitted in the absence of symptoms.  
Overall, prevalence is higher in women compared with men, especially 
among the young, and rates of up to 40% have been recorded among 
women aged 15-19 in Kisumu, Kenya. Infection has been associated with 
younger age at first sex, increased years of sexual activity, increasing 
number of lifetime partners, lack of circumcision (in men) and current or 
recent other STIs. 
HIV 
 HIV stands for Human Immunodeficiency Virus, the virus that 
causes AIDS. 
  H- Human 
  I – Immunodeficiency 
  V – Virus 
• HIV breaks down the body’s defence against infection and disease 
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– the body’s immune system by infecting specific white blood cells, 
leading to a weakened immune system.   
• When the immune system becomes weak or compromised, the 
 body loses its protection against illness. 
• As time passes, the immune system is unable to fight the HIV 
infection and person may develop serious and deadly, including 
other infections and some types of cancer. 
AIDS is an acronym for acquired immunodeficiency syndrome and     
refers to the most advanced stage of HIV infection. 
A – Acquired, (not inherited) to differentiate form a genetic or 
inherited condition that causes immune dysfunction. 
I – Immune, because it attacks the immune system and increases  
susceptibility to infection.  
 D – Deficiency of certain white blood cell in the immune system. 
S - Syndrome, a group of symptoms or illnesses that result from the 
HIV infection. 
Differences between HIV, HIV Infection, and AIDS 
• HIV is the virus that causes infection. 
• The person who is HIV- infected may have no signs of illness but 
can still infect others. 
• Most people who are HIV- infected will develop AIDS after a period 
 of time, which may be several months to more than 15 years. 
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• AIDS is a group of serious illnesses and opportunistic infections that 
develop after being infected with HIV for a long period of time. 
• A diagnosis of AIDS is based on specific clinical criteria and 
laboratory test results. 
Types of HIV 
 HIV-1 and HIV-2 are types of HIV. Both types are transmitted the 
same way, and both are associated with similar opportunistic infections 
and AIDS. HIV-1 is more common worldwide. HIV-2 is found 
predominantly in West Africa, Angola, Mozambique. 
Differences between HIV-1 and HIV-2 
 HIV-2 is less easily transmitted than HIV-1, and it is less 
pathogenic, meaning that the period between initial infection and illness is 
longer. In some areas, a person may be infected with both HIV-1 and   
HIV-2. While HIV-2 can be transmitted from an infected mother to her 
child, this appears to be rare (0% to 5% transmission rate in breastfed 
infants in the absence of any interventions). 
INTERACTION BETWEEN HSV2 AND HIV 
Biological and Clinical Research 
 HIV and HSV2 manifest a bi-directional interaction. HSV2 increases 
the efficiency of HIV acquisition and transmission whereas HIV may 
increase susceptibility to HSV2 and increase HSV2 shedding, HSV2 
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recurrence rate and severity of clinical manifestations. 
Effect of HIV infection on natural history of HSV2 
 HSV2 reactivation and duration of recurrences are significantly 
increased in HIV infected individuals. The frequency and severity of 
recurrences increases as CD4 cell count decreases. 
Effect of HIV infection on HSV2 transmission 
 HIV infection is also likely to increase transmission of HSV2, as 
there is evidence that the prevalence and quantity of genital HSV2 
shedding is significantly increased among HIV seropositive individuals. 
Effect of HSV2 on natural history of HIV disease 
 There is some evidence that inclusion of Valacyclovir in 
antiretroviral therapy may prolong survival in HIV seropositive individuals. 
One study has shown that HSV2 reactivation is associated with increases 
in plasma HIV1 RNA and intracellular gag mRNA and that plasma HIV1 
RNA level decreases significantly during treatment with Valacyclovir. As a 
result, it is possible that HIV progresses more rapidly in untreated HSV2 
positive individuals. However, evidence is inconclusive and more studies 
of the effect of episodic HSV2 therapy on HIV are needed, especially in 
developing countries. 
Effect of HSV2 on HIV transmission 
 A study of 12 men in the US infected with both HSV2 and HIV 
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showed that HIV RNA was present in almost all HSV2 lesions, suggesting 
that HIV transmission is enhanced in the presence of HSV2 lesions. HIV 
RNA is often present at high titres in genital lesions (independent of 
plasma RNA levels), but titres of both HIV1 and HSV2 fall rapidly on 
treatment with Valacyclovir, supporting the hypothesis that HSV2 
reactivation may play an important role in regulation of HIV1 on mucosal 
surfaces. Few data are available on the effect of subclinical HSV2 on HIV 
shedding and viral load, or on the relative effects of symptomatic and 
subclinical infection. It is plausible that the interaction between the two 
viruses differs in developed and developing countries, due to the role of 
other factors (such as circumcision, prevalence of other STIs and other 
tropical conditions or infections), and similar prospective studies of dually-
infected individuals are needed in developing countries. Further biological 
studies are also needed to define the mechanism by which HIV is secreted 
on the mucosal surface. 
MACROPHAGE 
 Greek: big eaters, from makros "large" + phagein "eat"; are white 
blood cells within tissues, produced by the division of monocytes. Human 
macrophages are about 21 microns in diameter. Monocytes and 
macrophages are phagocytes, acting in both non-specific defense (and 
innate immunity) as well as to help initiate specific defense mechanisms 
(or cell-mediated immunity) of vertebrate animals. Their role is to 
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phagocytose (engulf and then digest) cellular debris and pathogens either 
as stationary or mobile cells, and to stimulate lymphocytes and other 
immune cells to respond to the pathogen. 
Life cycle 
 When a monocyte enters damaged tissue through the endothelium 
of a blood vessel (a process known as the leukocyte extravasation), it 
undergoes a series of changes to become a macrophage. Monocytes are 
attracted to a damaged site by chemical substances through chemotaxis, 
triggered by a range of stimuli including damaged cells, pathogens and 
cytokines released by macrophages already at the site. At some sites such 
as the testis, macrophages have been shown to populate the organ 
through proliferation. Unlike short-lived neutrophils, macrophages survive 
longer in the body up to a maximum of several months. 
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Function 
 
Parts 
1. Pathogens 
2. Phagosome 
3. Lysosomes 
4. Waste material 
5. Cytoplasm 
6.  Cell membrane 
Steps of a macrophage ingesting a pathogen 
a. Ingestion through phagocytosis, a phagosome is formed 
b.  The fusion of lysosomes with the phagosome creates a 
 phagolysosome; the pathogen is broken down by enzymes 
c.  Waste material is expelled or assimilated (the latter not pictured) 
Role in specific immunity 
 Macrophages are versatile cells that play many roles. As 
scavengers, they rid the body of worn-out cells and other debris. They are 
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foremost among the cells that "present" antigen; a crucial role in initiating 
an immune response. As secretory cells, monocytes and macrophages 
are vital to the regulation of immune responses and the development of 
inflammation; they produce an amazing array of powerful chemical 
substances (monokines) including enzymes, complement proteins, and 
regulatory factors such as interleukin-1. At the same time, they carry 
receptors for lymphokines that allow them to be "activated" into single-
minded pursuit of microbes and tumour cells. 
 After digesting a pathogen, a macrophage will present the antigen 
(a molecule, most often a protein found on the surface of the pathogen, 
used by the immune system for identification) of the pathogen to the 
corresponding helper T cell. The presentation is done by integrating it into 
the cell membrane and displaying it attached to a MHC class II molecule, 
indicating to other white blood cells that the macrophage is not a 
pathogen, despite having antigens on its surface. 
 Eventually the antigen presentation results in the production of 
antibodies that attach to the antigens of pathogens, making them easier 
for macrophages to adhere to with their cell membrane and phagocytose. 
In some cases, pathogens are very resistant to adhesion by the 
macrophages. 
 The antigen presentation on the surface of infected macrophages 
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(in the context of MHC class II) in a lymph node stimulates  
TH1 (type 1 helper T cells) to proliferate (mainly due to IL-12 secretion 
from the macrophage). When a B-cell in the lymph node recognizes the 
same unprocessed surface antigen on the virus with its surface bound 
antibody, the antigen is endocytosed and processed. The processed 
antigen is then presented in MHCII on the surface of the B-cell. TH1 
receptor that has proliferated recognizes the antigen-MHCII complex (with 
co-stimulatory factors- CD40 and CD40L) and causes the B-cell to 
produce antibodies that help opsonisation of the antigen so that the virus 
can be better cleared by phagocytes. 
 Macrophages provide yet another line of defense against tumor 
cells and somatic cells infected with fungus or parasites. Once a T cell has 
recognized its particular antigen on the surface of an aberrant cell, the       
T cell becomes an activated effector cell, chemical mediators known as 
lymphokines that stimulate macrophages into a more aggressive form. 
These activated macrophages can then engulf and digest affected cells 
much more readily. The macrophage does not generate a response 
specific for an antigen, but attacks the cells present in the local area in 
which it was activated. 
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Macrophage 
Name of cell Location 
Dust cells/Alveolar macrophages Pulmonary alveolus of lungs 
Histiocytes Connective tissue 
Kupffer cells Liver 
Microglia Neural tissue 
Epithelioid cells Granulomas 
Osteoclasts Bone 
Sinusoidal lining cells Spleen 
Mesangial cells Kidney 
 
Involvement in symptoms of diseases 
 Due to their role in phagocytosis, macrophages are involved in 
many diseases of the immune system. For example, they participate in the 
formation of granulomas, inflammatory lesions that may be caused by a 
large number of diseases. Some disorders, mostly rare, of ineffective 
phagocytosis and macrophage function have been described. 
Macrophages are the predominant cells involved in creating the 
progressive plaque lesions of atherosclerosis. Macrophages also play a 
role in Human Immunodeficiency Virus (HIV) infection. Like T cells, 
macrophages can be infected with HIV, and even become a reservoir of 
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ongoing virus replication throughout the body. Macrophages are believed 
to help cancer cells proliferate as well. They are attracted to oxygen-
starved (hypoxic) tumour cells and promote chronic inflammation. 
Inflammatory compounds such as Tumor necrosis factor (TNF) released 
by the macrophage activates the gene switch nuclear factor-kappa B.    
NF-kB then enters the nucleus of a tumour cell and turns on production of 
proteins that stop apoptosis and promote cell proliferation and 
inflammation. 
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LITERATURE REVIEW 
 Stieneker et al., (2008) Methylmethacrylate (MMA) sulfopropyl-
methacrylate (SPM) copolymer nanoparticles were prepared by free 
radical polymerization. The conditions of preparation were varied with 
regard to the concentration of initiator and monomer, and copolymer 
composition. Nanoparticles with a yield greater than 80% were produced. 
The particles were characterized in terms of particle size, size distribution, 
particle charge (zetapotential) and molecular weight. The data were 
compared to pure polymethylmethacrylate (PMMA) nanoparticles. The 
copolymer composition was shown to influence particle size and particle 
charge. The influence of the total monomer amount in the polymerization 
medium on the particle size was characteristic up to a concentration of 2% 
depending on the solubility of MMA in water at the temperature of reaction. 
An increasing amount of total monomer led to particle sizes of 60-130 nm 
for low monomer concentrations (0.5%), depending on the proportion of 
SPM (0-10%), to 120-280 nm for higher total monomer concentrations 
(greater than 2%). Surface charge as well as particle size was influenced 
mainly by the proportion of the comonomer SPM in the copolymer. The 
negative surface charge increased from - 52 mV for pure PMMA 
nanoparticles to - 80 mV for the copolymer particles with an SPM content 
of 10%. In the same range of 10% SPM of the total monomer, the particle 
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sizes decreased from 187 to 100 nm. The concentration of the initiator up 
to a concentration of 0.3% showed no effect on the particle size of the 
resulting nanoparticle suspension. Higher concentrations led to intolerably 
large variability in the polymerization process. 
  Narendra Jain et al., (2008) HIV infected macrophages are 
considered as reservoirs for spreading the virus in AIDS patients. Tuftsin 
not only binds specifically to the mononuclear phagocytic cells but also 
enhances their natural killer activity. The purpose of this study is to explore 
the targeting potential and anti-HIV activity of Efavirenz (EFV) loaded, 
Tuftsin conjugated 5th generation poly (propyleneimine) dendrimers 
(TuPPI) in vitro. Tuftsin was chemically conjugated to 5th generation poly 
(propyleneimine) dendrimers (PPI). The entrapment efficiency of PPI and 
TuPPI were found to be 37.43±0.3% and 49.31±0.33%, respectively. 
TuPPI was found to slow down and prolong the in vitro release of EFV 
upto 144h against PPI, which releases the drug completely within 24 hr. 
TuPPI possessed negligible cytotoxicity as compared to that of PPI. The 
cellular uptake of TuPPI was found to be 34.5 times higher than that of the 
free drug in first 1hr and was significantly higher in HIV infected 
macrophages than that of uninfected cells. TuPPI was found to reduce the 
viral load by 99% at a concentration of 0.625ng/ml, which is due to the 
enhanced cellular uptake, reduced toxicity and the inherent anti-HIV 
activity of TuPPI. 
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 Davi Pereira de Santana et al., (2007) We report the development 
and validation of a new sensitive, accurate and precise HPLC method with 
ultraviolet detection for the determination of Indinavir sulfate (IND) in 
human plasma and its application to a bioequivalence study of a new 
generic formulation. The extraction of IND from plasma samples was 
achieved by using liquid-liquid extraction with a mean recovery of 73.9%. 
The lower limit of quantification was 0.05µg/mL. Bioequivalence between 
the products was determined by calculating 90% confidence intervals (CI) 
for the ratio of Cmax, AUC0-t and AUC0-inf values for the test and reference 
products, within the 0.80-1.25 interval proposed by ANVISA and FDA. 
Therefore the medications are bioequivalent and inter-exchangeable.  
  Yung-Chih Kuo et al., (2007) Permeability of the anti-human 
immunodeficiency virus (HIV) agents, including Stavudine (D4T), 
Delavirdine (DLV), and Saquinavir (SQV), across the in vitro  
blood–brain barrier (BBB) was studied. Here, the anti-HIV agents were 
incorporated withpolybutylcyanoacrylate (PBCA) nanoparticles (NPs), 
methylmethacrylate- sulfopropylmethacrylate (MMA-SPM) NPs, and solid 
lipid nanoparticles (SLNs). Transport of the anti- HIV agents across BBB is 
a key factor in their applications to the therapy of the acquired 
immunodeficiency syndrome (AIDS). Experimental results revealed that 
Chapter III Literature Review 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
50
the drug order of the loading efficiency (LE) on PBCA and MMA-SPM was 
D4T >DLV> SQV. For the entrapment efficiency (EE) in SLNs, this order 
was reversed. Also, LE of D4T on MMA-SPM was larger than that on 
PBCA; however, the reverse was true for DLV and SQV. As the particle 
size increased, LE decreased and EE increased. For a fixed drug carrier, 
an increase in the particle size yielded a decrease in the BBB permeability 
coefficient of the anti-HIV agents. Moreover, enhancement in the BBB 
permeability was on the carrier order of PBCA >MMA-SPM> SLNs for 
D4T, and for DLV and SQV, the order became PBCA > SLNs > MMA-
SPM. PBCA, MMA-SPM, and SLNs were efficacious carriers of D4T, DLV, 
and SQV to meliorate BBB permeability by 3–16 folds, indicating the 
clinical potential of the present NP formulations for the AIDS treatment. 
 Lipa Shah et al., (2006) Aim to developing poly (ethylene oxide) - 
modified poly (epsilon-caprolactone) (PEO-PCL) nanoparticulate system 
as an intracellular delivery vehicle for Saquinavir, an anti-HIV protease 
inhibitor. The PEO-PCL nanoparticles had a smooth surface and spherical 
shape and showed a relatively uniform size distribution with a mean 
particle diameter of approximately 200nm. Intracellular Saquinavir 
concentrations when administered in the nanoparticle formulation were 
significantly higher than from aqueous solution. PEO-PCL nanoparticles 
provide a versatile platform for encapsulation of Saquinavir and 
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subsequent intercellular delivery in Mo/Mac cells. 
 Gladys Granero et al., (2006). The absolute bioavailability of the 
prodrug Valacyclovir, the l-Valyl ester of acyclovir, after oral administration 
is 54.5%. Since premature hydrolysis of this prodrug in the intestinal lumen 
may be a possible reason for its incomplete bioavailability and the 
chemical and enzymatic stability of the Valacyclovir has been investigated. 
Release rates were investigated in both phosphate buffers with varying pH 
as well as in human and dog gastrointestinal fluids. The stability of the 
prodrug was found to be dependent on pH. This prodrug is chemically 
stable along the acidic pH side (under 4), while the prodrug degrades in 
alkaline medium through a base-catalyzed pseudo-first-order kinetics. The 
degradation of the prodrug Valacyclovir progressed faster in intestinal fluid 
than in phosphate buffer at the same pH. There was no appreciable 
release of Valacyclovir neither in the human and dog stomach contents 
nor in phosphate buffers at pHs fewer than 4, although its degradation was 
fastest in the human and dog stomach contents. In light of this result, we 
can conclude that the degradation of the Valacyclovir in the upper 
intestinal lumen is probably one of the causes of its poor bioavailability. 
 Ghania Degobert et al., (2006). Freeze-drying has been 
considered as a good technique to improve the long-term stability of 
colloidal nanoparticles. The poor stability in an aqueous medium of these 
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systems forms a real barrier against the clinical use of nanoparticles. This 
article reviews the state of the art of freeze-drying nanoparticles. It 
discusses the most important parameters that influence the success of 
freeze-drying of these fragile systems, and provides an overview of 
nanoparticles freeze-drying process and formulation strategies with a 
focus on the impact of formulation and process on particle stability.   
 Yung-Chih Kuo et al., (2006). Effect of size of nanoscaled 
polybutylcyanoacrylate (PBCA) and methylmethacrylate–
sulfopropylmethacrylate (MMA–SPM) on the permeability of Zidovudine 
(AZT) and Lamivudine (3TC) across the blood–brain barrier (BBB) was 
investigated. Also, influence of alcohol on the permeability of AZT and 3TC 
incorporated with the two polymeric nanoparticles (NPs) was examined. 
The loading efficiency and the permeability of AZT and 3TC decreased 
with an increase in the particle size of the two carriers. By employing 
PBCA NPs, the BBB permeability of AZT and that of 3TC became, 
respectively, 8–20 and 10–18 folds. Application of MMA–SPM NPs leaded 
to about 100% increase in the BBB permeability of the two drugs. In the 
presence of 0.5% ethanol, 4–12% enhancement in the BBB permeability 
of the two drugs was obtained in the current carrier-mediated system. 
Yiguang Jin et al., (2006). Self-assembled drug delivery systems 
(SADDS) were designed in the paper. They can be prepared from the 
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amphiphilic conjugates of hydrophilic drugs and lipids through self-
assembling into small-scale aggregates in aqueous media. The 
outstanding characteristic of SADDS is that they are nearly wholly 
composed of amphiphilic prodrugs. The self-assembled nanoparticles 
(SAN) as one of SADDS had been prepared from the lipid derivative of 
acyclovir (SGSA) in the previous paper. They were further studied on the 
properties and the in vitro/in vivo behavior in this paper. The SAN kept the 
physical state stable upon centrifugation or some additives including some 
inorganic salts, alkaline solutions, surfactants and liposomes except for 
HCl solution, CaCl2 solution and animal plasma. Autoclave and bath heat 
for sterilization hardly influenced the SAN. However, gamma-irradiation 
strongly destroyed the structure of SAN and SGSA was degraded. SGSA 
in SAN showed good stability in weak acidic or neutral buffers although it 
was very sensitive to alkaline solutions and Carboxyl ester enzymes, the 
half-lives (t1/2) of which in the buffer at pH 7.4, the alkaline solution at pH 
12.0, pig liver carboxylester enzyme solution, rabbit plasma, and rabbit 
liver tissue homogenate were 495, 21, 4.7, 25 and 8.7 h, respectively. 
Compared with SGSA in a disordered state, the specific bilayer structures 
of SAN could protect SGSA from hydrolysis through hiding the sensitive 
ester bonds. The SAN showed hemolytic action because the amphiphilic 
SGSA could insert into rabbit erythrocyte membranes. Both the high 
concentration of SGSA in samples and the long incubation time improved 
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hemolysis. No hemolysis was observed if the additional volume of the SAN 
was less than 10% of rabbit whole blood in spite of the high concentration 
of SGSA. Plasma proteins could interfere the interaction between the SAN 
and erythrocytes by binding the SAN. The in vitro antiviral activity of 
acyclovir SAN was limited possibly because of the weak hydrolysis of 
SGSA in Vero cells, and the SAN showed a little cell toxicity possible due 
to the amphiphilicity of SGSA. A macrophage cell line of QXMSC1 cells 
showed uptake of the SAN but not significantly. The SAN were rapidly 
removed from blood circulation after bolus i.v administration to rabbits with 
the very short distribution t1/2 (1.5 min) and the elimination t1/2 (47 min). 
The SAN were mainly distributed in liver, spleen and lung after i.v 
administration, and SGSA was eliminated slowly in these tissues (t1/2, 
about 7 h). It would appear that the nanosized SAN were trapped by the 
mononuclear phagocyte system. SADDS including SAN combine 
prodrugs, molecular self-assembly with nanotechnology, and hopefully 
become novel drug delivery approaches. 
 Yung-Chih Kuo et al., (2005). Loading efficiency (LE) of Stavudine 
(D4T), a human immunodeficiency antiretroviral agent, on the external 
surfaces of Polybutylcyanoacrylate (PBCA) and Methylmethacrylate-
Sulfopropylmethacrylate (MMA-SPM) was investigated. The experimental 
results indicate that the larger the polymeric nanoparticles (NPs), the 
smaller LE of D4T on the two kinds of biomaterials. Freeze drying of the 
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two NPs, however, yields an increase in particle size and an increase in 
LE of D4T, in general. Preservation of the two D4T-loaded NPs through 
cold storage at 4 ◦C over 6 weeks leads to an increase in particle size and 
a decrease in LE ofD4T. LE of D4T on both of the two NPs decreases with 
a variation in pH value from pH 7.2 of loading medium. LE of D4T on 
MMA-SPM NPs is larger than that on PBCA NPs at pH 7.4; and for the 
case of variation in pH value of loading medium from pH 7.2, the extent of 
decrease in LE of D4T for MMA-SPM NPs is higher than that on PBCA 
NPs. These outcomes imply that for oral administration, D4T-loaded MMA-
SPM NPs may be more advantageous than D4T-loaded PBCA NPs, and 
D4T-loaded PBCA NPs may be more favorable than D4T-loaded MMA-
SPM NPs for intravenous injection. 
 Bergshoeff et al., (2004). So far, no pediatric doses for Indinavir 
combined with Ritonavir have been defined. This study evaluated the 
pharmacokinetics of 400 mg of Indinavir/m2 combined with 125 mg of 
Ritonavir/m2 every 12 h (q12h) in 14 human immunodeficiency virus type 
1-infected children. The area under the concentration-time curve from 0 to 
24 h and the minimum concentration of drug in serum for Indinavir were 
similar to those for 800 mg of indinavir–100 mg of Ritonavir q12h in adults, 
while the maximum concentration of drug in serum was slightly decreased, 
with geometric mean ratios (90% confidence intervals in parentheses) of 
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1.1 (0.87 to 1.3), 0.96 (0.60 to 1.5), and 0.80 (0.68 to 0.94), respectively. 
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 Norbert Dinauer et al., (2004). Aim to study about intracellular 
tracking of protamine / anisense oligonucleotide nanoparticles in inhibitory 
effect on HIV-1 transactivation. Membrane transport of antisense 
oligonucleotide (AS-ODN) is a special carrier for intracellular delivery. 
They have developed a delivery system for AS-ODN and their 
phosphorothioate analogues (AS-PTO) directed against HIV-1 tat mRNA 
for efficient transfection of HIV-1 target cells. These results demonstrate 
that protamine/AS-ODN nanoparticles are useful for future therapeutical 
application to inhibit viral gene expression.                
 Sibel Ozkan et al.,  (2003). A specific, sensitive, simple, and rapid 
HPLC method has been developed for the determination of valacyclovir 
(VACL) in raw material, pharmaceutical dosage forms, and human serum, 
in order to carry out drug dissolution studies from tablets. The 
chromatographic separation was achieved with acetonitrile: methanol: 
0.067M KH2PO4 (27:20:53, v/v/v) adjusted to pH 6.5 with 3M NaOH as 
mobile phase, a Waters Spherisorb CIS column, and UV detection at 
244nm. Etodolac was used as an internal standard. Linearity range was 5-
20,000 ngmL. Limit of detection obtained was 0.38 and 0.14ngmL in 
mobile phase and spiked human serum samples, respectively. The 
described method can be readily applied, without any interference from the 
excipients, for the determination of the drug in tablets, human serum 
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samples, and drug dissolution studies.  
  Veronique Joly et al., (2002). We compared the efficacy and the 
toxicity of Zidovudine (AZT) versus Stavudine (d4T), in combination with 
Lamivudine (3TC) and Indinavir, in AZT-, dideoxyinosine (ddI)-,and/or 
dideoxycytosine (ddC)- experienced patients in a randomized comparative 
multicenter trial. One hundred seventy human immunodeficiency virus type 
1 (HIV-1)-infected patients, who had received AZT, ddI, and/or ddC for at 
least 6 months but were naïve for d4T, 3TC, and protease inhibitors, were 
randomized to AZT at 250 to 300 mg twice daily, 3TC at 150 mg twice 
daily, and Indinavir at 800 mg every 8 h or to d4T at 40 mg twice daily, 
3TC at 150 mg twice daily, and Indinavir at 800 mg every 8 h. The primary 
endpoint was time to virological failure, defined as plasma HIV-1RNA 
levels of >5,000 copies/ml after at least 8 weeks of antiretroviral therapy. 
Additional endpoints were change from baseline in CD4 cell counts, AIDS-
defining events and adverse events, and proportion of patients with HIV-1 
RNA levels of <500 copies/ml and HIV-1 RNA levels of <50 copies/ml. At 
week 80, 15 patients in the AZT arm and 14 patients in the d4T arm had 
reached the primary endpoint, and time to virological failure did not differ 
between the two arms (P - 0.98). In the d4T and in the AZT arms, 67 and 
73% of patients, respectively, had HIV-1 RNA levels of <500 copies/ml (P -
0.50). The median change from baseline in CD4 cell count was 195 -106 
and 175 - 106/liter for the d4T- and AZT-containing arms, respectively. 
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The proportions of patients with HIV-1 RNA levels of <50 copies/ml at 
weeks 8, 16, and 24 were similar in the two arms. The occurrence of 
serious adverse events was not significantly different between arms. In 
conclusion, in these patients heavily pretreated with AZT, switching from 
AZT to d4T when initiating Indinavir and 3TC did not bring any additional 
benefit compared to maintaining AZT. 
          Juan Irache et al., (2001). Ganciclovir is one of the most widely 
used antiviral drugs for the treatment of cytomegalovirus retinitis. Due to 
its short half-life in the vitreous, frequent administrations are necessary to 
maintain the therapeutic levels. In this context, the aim of this study was to 
characterize and in vitro evaluate the drug release properties of three 
different formulations of Ganciclovir-loaded albumin nanoparticles.These 
carriers were prepared by a coacervation method and chemical cross-
linking with glutaraldehyde. Depending on the step where the drug and/or 
cross-linking agent were added three different formulations were obtained, 
named models A, B and C. For model A nanoparticles, Ganciclovir was 
incubated with the just-formed albumin nanoparticles. For the other two 
types of nanoparticulate formulations, the drug was added to a solution of 
albumin (model B) and glutaraldehyde (model C) prior the formation of the 
carriers by coacervation. In all cases, the size of the different 
nanoparticulate formulations was comprised between 200 and 400 nm and 
the yield ranged from 50%, in model A, to 65% in model B. Concerning the 
Ganciclovir loading, model B nanoparticles offered the higher capacity to 
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carry this antiviral drug (around 30 mg Ganciclovir /mg nanoparticle). On 
the contrary, the drug loading calculated for model A nanoparticles was 
only 14.6 mg/mg. The in vitro release profiles of the nanoparticles showed 
a biphasic pattern, with an initial and rapid release, followed by a slower 
step for up 5 days. This burst effect was especially relevant in model A 
(around 60% in 1 h), followed by model B (40%) and less important in 
model C (20%). The addition of trypsin to the release medium did not have 
a significant influence on the release characteristics. However, the release 
of the drug was increased in acidic or basic mediums, due to the disruption 
of the covalent binding between Ganciclovir and the protein matrix via 
glutaraldehyde. This strong linkage was also confirmed by TLC 
experiences. In summary, a first step of incubation between the drug and 
the protein, prior the preparation of nanoparticles, enabled us to obtain 
albumin carriers able to release Ganciclovir in a sustained way. 
 Uwe wintergerst et al., (2000). Indinavir concentrations were 
determined in plasma and saliva over a random period of 4 h. On average, 
levels in saliva were 70%, 38% of the corresponding levels in plasma. 
These findings suggest that saliva might serve as an appropriate 
specimen for monitoring of plasma Indinavir levels in patients treated with 
Indinavir. 
 Zhang Zhi-Rong et al., (1999) To prepare Valaciclovir 
polybutylcyanoacrylate nanoparticles (VACV-PBCA-NP) with liver 
targeting and hepatocyte permeable characteristics. Emulsion 
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polymerization method was employed to prepare VACV-PBCA-NP. The 
formula and preparation conditions were optimized by using the uniform 
design. The organ distribution of the intravenously injected VACV-PBCA-
NP and VACV in animal was determined using HPLC. The hepatocytes 
permeability of VACV-PBCA-NP was demonstrated by cell uptake 
experiment in vitro. The drug loading and the drug embedding ratio of 
VACV-PBCA-NP were 11.20% and 84.85% respectively, with an average 
diameter of 10 4.77nm±11.78nm. The releasing characteristics in vitro 
fitted the two-phase kinetics. 74.49% of the drug was found to localize in 
the liver 15min after the administration of VACV-PBCA-NP in the mice. 
Compared with VACV, VACV-PBCA-NP showed distinct characteristic of 
sustained-release in vivo and the drug entering hepatocytes were also 
greatly increased. VACV-PBCA-NP has the characteristic of liver targeting 
and can increase the permeability of VACV to hepatocytes. 
 Nigel Phillips et al., (1998). Solid lipid nanoparticles (SLNs) were 
prepared using trilaurin as the SLNs solid core and a mixture of neutral 
and negatively charged phospholipid. To produce SLNs with a poly 
(ethylene glycol) (PEG) coating, PEG was incorporated in SLNs using 
dipalmitoyl- phosphatidylethanolamine-N-[poly (ethylene glycol) 2000] (PE-
PEG). 3%-azido-3% deoxythymydine palmitate (AZT-P) with [3H]-AZT-P 
as tracer were synthesized and incorporated in SLNs. Their subsequent 
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retention in SLNs with and without PEG was determined after incubation in 
50% bovine plasma. Biodistribution studies were performed in mice using 
free AZT-P, AZT-P incorporated in SLNs or AZT-P incorporated in PE-
PEG coated SLNs (SLN-PE-PEG). The presence of PE-PEG significantly 
reduced the SLN zeta potential from -22 to -5 mV. Although AZT-P was 
rapidly released from SLNs during incubation in bovine plasma, the 
release rate was significantly slower in SLN-PE-PEG. AZT-P was rapidly 
removed from blood following i.v. injection in mice. The decrease in AZT-P 
blood level was biphasic and rapid, and the major excretory route of AZT-
P was the kidney. Higher levels were observed after i.v. injection of AZT-P 
incorporated in SLNs. This effect was further increased using SLN-PE-
PEG. Both SLN and SLN-PE-PEG incorporation of AZT-P significantly 
decreased the urinary excretion of AZT-P and increased the localization of 
AZT-P in the liver. The results obtained in this study indicate that using 
SLNs as a drug carrier increases the bioavailability of incorporated AZT-P, 
and that the pharmacokinetic behaviour of the incorporated drug can be 
modified by changing the surface characteristics of SLNs by using the 
amphiphilic solvation enhancer PE-PEG.  
 
 
  Oh et al., (1998). The effect of current, its magnitude and 
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penetration enhancers (propylene glycol / oleic acid) on the transdermal 
flux of AZT (Zidovudine) across hairless mouse skin was studied and the 
results were compared. The in vitro iontophoretic flux from AZT solution 
increased to about 5–40 fold that obtained by passive diffusion, depending 
on the magnitude of current density. When the donor side was karaya gum 
matrix, instead of solution, the flux enhancement effect by iontophoresis 
was much smaller. Incorporation of penetration enhancers into the matrix 
increased the passive flux 2–50 fold, depending on the amount of 
penetration enhancers in the matrix. These enhancers worked 
synergistically with iontophoresis in the transdermal transport: a much 
larger flux than that expected from a simple additive effect was observed. 
Electrical resistance data from our previous work is utilized to further 
discuss this synergistic effect. 
 Kreuter et al., (1997). Reticuloendothelial cells play an important 
role in the immunopathogenesis of AIDS. For this reason, a targeted 
delivery of antiviral drugs to these cells should significantly improve 
therapy of AIDS. The objective of the present study was to investigate the 
possibility of specific drug targeting of antiviral drugs to the 
reticuloendothelial cells by the oral route. Hexylcyanoacrylate 
nanoparticles were used as colloidal drug carriers for Azidothymidine 
(AZT). 14C-labelled AZT was bound to nanoparticles using bis  
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(2-ethylhexyl) sulfosuccinate sodium as surfactant. The radioactivity in 
several organs including those containing large numbers of macrophages 
was measured after peroral administration of the nanoparticle preparation 
and compared to a [14C] AZT control solution containing the same 
components without the nanoparticles. In the liver the area under the 
curve (AUC) of [14C] AZT was 30% higher when the drug was bound to 
nanoparticles than after administration of the solution. In addition, higher 
[14C] AZT concentrations were observed after 1 hour and at later time 
points in blood and brain when nanoparticles were used compared to the 
control solution. These results indicate that nanoparticles are a promising 
drug targeting system for nucleoside analogues. Furthermore, the increase 
in drug availability at sites containing abundant macrophages, e.g. in the 
blood and in the brain, may allow a reduction in dosage and a decrease in 
systemic toxicity. 
 Kreuter et al., (1997) Methylmethacrylate (MMA) sulfopropyl-
methacrylate (SPM) copolymer nanoparticles were prepared by free 
radical polymerization and the loading characteristics of the muscarinic 
agonists arecaidine propargyl ester (APE) and pilocarpine were 
investigated. The loading efficiency was mainly influenced by the 
concentration of the copolymer carrier system and followed Langmuir’s 
adsorption equation. The in vitro drug release was mainly influenced by 
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the composition of the acceptor phase used and the nanoparticle content 
of the donor phase. The bound drug was released from the carrier by 
competitive replacement by other ions from the binding sites of the 
particles. By this mechanism the nanoparticle system achieved a 
prolonged drug release, which was not the result of the increased viscosity 
at higher nanoparticle concentrations. 
 Kreuter et al., (1997) Copolymer nanoparticles were investigated as 
carrier systems for the topical ophthalmic application of the muscarinic 
agonists arecaidine propargyl ester (APE) and (S)-(+)-aceclidine in rabbits 
and compared to conventional eye drop preparations. The copolymer 
nanoparticles were prepared by free radical polymerization of 
methylmethacrylate (MMA) and sulfopropylmethacrylate (SPM). The in-vivo 
activity of the drug-containing carrier systems was tested by the 
measurement of the miotic effect observed after local administration in 
rabbits. It has been found that the copolymer nanoparticles were able to 
produce a significant increase of the ocular APE bioavailability as 
determined by the area under the miosis-time-curve (AUC). The 
nanoparticle preparations were tolerated without any irritating effect in the 
rabbit eye. Besides the copolymer nanoparticles, different formulations 
containing bioadhesive or viscosity-enhancing polymers with and without 
additional nanoparticles were tested. The administration of APE-loaded 
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copolymer nanoparticles was found to be equivalent in efficacy to solutions 
containing the soluble polymers without nanoparticles. The combination of 
the nanoparticles with bioadhesive polymers further increased the ocular 
drug bioavailability. Hyaluronic acid alone or in combination with copolymer 
nanoparticles was observed to be the most effective soluble polymer for 
ophthalmic application by enhancing the AUC of miosis-time-curve 2-fold. 
Similar effects induced by the carrier systems were obtained with (S)-(+)- 
aceclidine. However, the magnitude of the enhancement of the miotic effect 
that is achievable by the binding of the drug to nanoparticles over free drug 
is much more pronounced with the short acting drug APE than with (S)-(+)-
aceclidine. 
 Hagen Von Briesen et al., (1996). Polyhexylcyanoacrylate 
nanoparticles loaded with either the human immunodeficiency virus (HIV) 
protease inhibitor Saquinavir (Ro 31-8959) or the nucleoside analog 
Zalcitabine (2,3-dideoxycytidine) were prepared by emulsion 
polymerization and tested for antiviral activity in primary human 
monocytes/macrophages in vitro. Both nanoparticulate formulations led to 
a dose-dependent reduction of HIV type 1 antigen production. While 
nanoparticle-bound Zalcitabine showed no superiority to an aqueous 
solution of the drug, a significantly higher efficacy was observed with 
Saquinavir-loaded nanoparticles. In acutely infected cells, an aqueous 
Chapter III Literature Review 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
67
solution of Saquinavir showed little antiviral activity at concentrations 
below 10 nM, whereas the nanoparticulate formulation exhibited a good 
antiviral effect at a concentration of 1 nM and a still-significant antigen 
reduction at 0.1 nM (50% inhibitory concentrations 5 4.23 nM for the free 
drug and 0.39 nM for the nanoparticle-bound drug). At a concentration of 
100 nM, Saquinavir was completely inactive inchronically HIV-infected 
macrophages, but when bound to nanoparticles it caused a 35% decrease 
in antigen production. Using nanoparticles as a drug carrier system could 
improve the delivery of antiviral agents to the mononuclear phagocyte 
system in vivo, overcoming Pharmacokinetic problems and enhancing the 
activities of drugs for the treatment of HIV infection and AIDS. 
 Jean-Christophe Leroux et al., (1995). CGP 57813 is a 
Peptidomimetic inhibitor of HIV-1 inhibitor protease. This lipophilic 
compound was successfully entrapped into poly (D, L- Lactic acid) (PLA) 
and pH sensitive methacrylic acid copolymers nanoparticles. The 
intravenous administration to mice of PLA nanoparticles resulted in a 2-
fold increase of the area under the plasma concentration-time curve 
compared to a control solution. In vitro, these nanoparticles dissolved 
completely within 5 min at pH 5.8. PLA NPs which is insoluble in GIT.          
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DRUG PROFILE 
VALACYCLOVIR HYDROCHLORIDE 
 Hydrochloride salt of L-Valyl ester of the antiviral drug Acyclovir 
Chemical Name :  Valacyclovir hydrochloride is L-Valine,         
2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) 
methoxy] ethyl ester, monohydrochloride. 
Structure : 
 
 
 
Molecular Formula   :    C
13
H
20
N
6
O
4
• HCl 
Molecular Weight     :    360.80 
Description and Solubility: 
           Valacyclovir hydrochloride is a white to off-white powder and 
maximum solubility in water at 25°C is 174 mg/mL. 
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MECHANISM OF ANTIVIRAL ACTION 
          Valacyclovir hydrochloride is rapidly converted to acyclovir which 
has demonstrated antiviral activity against herpes simplex virus types 
HSV-1 and HSV-2 and Varicella-zoster virus (VZV) both in vitro and         
in vivo. The inhibitory activity of Acyclovir is highly selective due to its 
affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. 
This viral enzyme converts Acyclovir into Acyclovir monophosphate, a 
nucleotide analogue. The monophosphate is further converted into 
diphosphate by cellular guanylate kinase and into triphosphate by a 
number of cellular enzymes. In vitro, Acyclovir triphosphate stops 
replication of herpes viral DNA.  
This is accomplished in 3 ways:  
1)  Competitive inhibition of viral DNA polymerase,  
2)  Incorporation and termination of the growing viral DNA chain,  
3)  Inactivation of the viral DNA polymerase. The greater antiviral 
activity of Acyclovir against HSV compared with VZV is due to its 
more efficient phosphorylation by the viral TK. 
CLINICAL PHARMACOLOGY 
           After oral administration, Valacyclovir hydrochloride is rapidly 
absorbed from the gastrointestinal tract and nearly completely converted 
to Acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. 
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PHARMACOKINETICS 
 Pharmacokinetics of Valacyclovir and Acyclovir after oral 
administration. 
ABSORPTION AND BIOAVAILABILITY 
 After oral administration, Valacyclovir hydrochloride is rapidly 
absorbed from the gastrointestinal tract. The absolute bioavailability of 
Acyclovir after administration is 54.5% ± 9.1% as determined following a  
1-gram oral dose of Valacyclovir hydrochloride. Acyclovir bioavailability 
from the administration of Valacyclovir hydrochloride is not altered by 
administration with food (30 minutes after an 873 Kcal breakfast, which 
included 51 grams of fat). There is no accumulation of Acyclovir after the 
administration of Valacyclovir at the recommended dosage regimens in 
healthy volunteers with normal renal function. 
DISTRIBUTION  
The binding of Valacyclovir to human plasma proteins ranged from 
13.5% to 17.9%. 
PROTEIN BINDING 
Valacyclovir  — Low (13 to 18%)  
 Acyclovir  — Low (9 to 33%). 
METABOLISM 
  After oral administration, Valacyclovir hydrochloride is rapidly 
absorbed from the gastrointestinal tract. Valacyclovir is converted to 
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Acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. 
Acyclovir is converted to a small extent to inactive metabolites by 
Aldehydeoxidase and by alcohol and Aldehyde dehydrogenase. Neither 
Valacyclovir nor Acyclovir is metabolized by cytochrome P450 enzymes.  
HALF-LIFE 
Valacyclovir: Less than 30 minutes  
 Acyclovir: After administration of Valacyclovir 
 Normal renal function—2.5 to 3.3 hours  
 End-stage renal disease—approximately 14 hours  
 Geriatric patients (65 to 83 years of age)—3.3 to 3.7 hours  
Time to peak concentration 
 1.6 to 2.1 hours 
PEAK PLASMA CONCENTRATIONS 
Valacyclovir: 
 Plasma concentrations of unconverted valacyclovir are low, with 
peak concentrations of less than 0.5 mcg per mL (mcg/mL) after any dose. 
Plasma concentrations are nonquantifiable within 3 hours after 
administration.  
Acyclovir: 
 Peak plasma concentrations are not proportional to the dose. 
After a single dose of Valacyclovir. 
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 500 mg : Approximately 3.3 mcg/mL  
 1 gram : 4.8 to 5.6 mcg/mL  
After multiple doses of Valacyclovir 
 500 mg : Approximately 3.7 mcg/L  
 1 gram : 5 to 5.5 mcg/mL 
ELIMINATION  
Valacyclovir 
        Less than 1% of Valacyclovir is recovered unchanged in the urine 
over 24 hours. 
In dialysis 
 It is not known if peritoneal dialysis removes Valacyclovir from the 
lood. 
Acyclovir 
Renal; Acyclovir accounts for 80 to 89% of the total urinary 
recovery. There was no accumulation of Acyclovir after repeated 
administration of Valacyclovir in patients with normal renal function. 
In dialysis 
 Hemodialysis—during 4-hour hemodialysis session, approximately 
one third of Acyclovir in the body is removed. The half-life of Acyclovir is                       
approximately 4 hours during hemodialysis. 
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Peritoneal dialysis 
           Chronic ambulatory peritoneal dialysis (CAPD) and continuous 
arteriovenous hemo filtration/dialysis (CAVHD) do not substantially remove 
Acyclovir, with pharmacokinetic parameters resembling those observed in 
patients with end-stage renal disease not receiving hemodialysis. 
 ADVERSE EFFECTS 
                            Nausea 
                            Headache    
                            Vomiting   
                            Dizziness    
                            Abdominal pain 
INCIDENCE LESS FREQUENT 
Dysmenorrhea: Painful menstruation, including (abdominal cramps; 
diarrhea; nausea) 
INCIDENCE RARE 
 Aplastic anemia 
 Chest pain; chills; cough; fever; headache; shortness of breath 
 Decreased consciousness 
 (Reduced mental alertness)— in patients with renal insufficiency 
Hepatitis with liver function test abnormalities 
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 Flu-like symptoms; unusual tiredness; yellow eyes or skin. 
 Renal insufficiency 
 Lower back/side pain; decreased frequency/amount of urine — 
manifested by increased serum creatinine. 
Thrombocytopenia: 
 Black, tarry stools; chest pain; chills; cough; fever 
Incidence not determined 
 Observed during clinical practice; estimates of frequency cannot be 
determined.       
Acute hypersensitivity reactions and Anaphylaxis 
 Fast heartbeat; swelling of face; wheezing; difficulty in breathing or 
swallowing; skin rash; itching. 
Aggressive behavior 
  Changes in behavior, especially in interactions with other people 
Facial edema 
 Swelling or puffiness of face 
Hallucinations 
 Seeing, hearing, or feeling things that are not there 
Hemolytic anemia, Microangiopathic  
 Back, leg, or stomach pains; chills; difficulty breathing; swelling of 
face, hands, legs, or feet. 
Hypertension 
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 High blood pressure 
Skin reactions such as erythema multiforme, photosensitivity, or 
rash:   
 Redness of the skin 
 Tachycardia 
 Fast, pounding, or irregular heartbeat; lightheadedness when 
getting up from a lying or sitting position  
Strength(s) usually available 
 500 mg [Valtrex] 
 1 gram [Valtrex] 
Packaging and storage 
 Store between 15 and 25 °C (59 and 77 °F), in a tight container. 
Protect from light. 
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MONOMER PROFILE 
METHYL METHACRYLATE 
Synonyms   : 2-methacrylic acid methyl ester, 2-Propenoic acid,                                 
                                   Methyl 2- methylpropenoate.  
Structure 
 
 Methyl methacrylate is an organic compound with the formula 
CH2=C (CH3) CO2 CH3. This colourless liquid, the methyl ester of 
methacrylic acid (MAA) is the monomer for the production of the 
transparent plastic polymethyl methacrylate (PMMA). 
IUPAC Name  :  methyl 2-methlprop-2-enote 
Molecular formula  :  C5H8O2  
Appearance   :  Colourless liquid  
Molar mass   :  100.12 g/mol 
Density   :  0.94 g/cm3 
Melting point  :  -480C (225 K) 
Boiling point  :  1010C (374 K) 
Solubility in water  :  1.5g/100 ml (250C)   
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Viscosity   :  0.6 cp at 200C 
Category                            :  Used for preparation of Polymethyl 
methacrylate. 
    :  Used for production of co-polymers.   
3-SULFOPROYLE METHACRYLATE, POTASSIUM SALT 
Structure 
 
 Water soluble monomer. Used to introduce polar into polymer 
chains, confer shear stability to aqueous polymer dispersions. 
Mol. Formula :  C7H11KO5S 
Mol. Wt. :  246.3 
Melting Point :  2950C 
Appearance :  White powder 
Solubility : Freely soluble in water 
Stability :  Stable, incompatible with peroxides, strong acids, 
strong oxidizing agents. 
Storage :  Store at 2-80C temperature. Protect from the 
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Sunlight 
Category : Used for production of Co-polymers.  
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PREFORMULATION STUDIES 
IDENTIFICATION TEST 
 Comparing of infrared spectrum of pure sample with the reference 
spectrum of Valacyclovir hydrochloride. 
EQUIPMENT 
1. FT- IR- Hydraulic pellet press. 
2. Shimadzu, 8400 S. 
PROCEDURE 
 The pure sample obtained is thoroughly mixed with completely 
dried potassium bromide and the pellet was prepared and the nature of the 
drug was analyzed by means of Shimadzu FT/IR. 
COMPATIBILITY STUDIES 
 Infrared spectra matching approach was used for detection of any 
possible chemical interaction between the drug and polymer. A physical 
mixture (1:1) of the drug and polymer was prepared and mixed with 
suitable quantity of potassium bromide. About 100mg of the mixture was 
compressed to form a transparent pellet using a hydraulic press at 6 tons 
pressure. It was scanned from 4000 to 400 cm-1 in Shimazu FT/IR 
spectrophotometer. The IR spectrum of the physical mixture was 
compared with those of pure and polymers and matching was done to 
detect any appearance or disappearance of peaks. 
Chapter VI       Preformulation Studies  
HSV2 inhibition with HIV Suppressing Nanoparticles For Targeted Drug Delivery Of 
Macrophages/ Monocytes 
 
78
 
Fig. 6. IR SPECTRUM OF VALACYCLOVIR . HCl 
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Fig. 7.  IR SPECTRUM OF POLYMER (MMA-SPM) 
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Fig. 8. IR SPECTRUM OF VALACYCLOVIR. HCl WITH MMA - SPM 
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FT-IR SPECTRAL ANALYSIS 
Result 
 The compatibility between the drug and the selected polymers was 
evaluated using FT-IR peak matching method. The IR spectra of pure 
drug, polymers and the physical mixtures are shown in spectra. There was 
no appearance or disappearance of peaks in polymer and drug mixture, 
which confirmed the absence of any chemical interaction between drug 
and polymers.   
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EXPERIMENTAL WORK 
MATERIALS & EQUIPMENTS USED FOR PREPARATION AND EVALUATION 
OF NANOPARTICLES 
Materials Used 
Materials Source 
Valacyclovir.Hcl Aurobindo Pharmaceuticals, Hyderabad.  
Methyl Methacrylate Loba Chem. Pvt. Ltd, Mumbai.  
Potassium dihydrogen 
Orthophosphate, Purified HiMedia Lab. Pvt. Ltd, Mumbai. 
3- Sulfopropylmethacrylate 
Potassium Salt Sigma-Aldrich, USA. 
Ammonium Persulphate Fine Chem. Industry, Chennai. 
D-Mannitol HiMedia Laboratories Pvt. Ltd. Mumbai.
Acetonitrile  Ranbaxy Fine Chemicals Ltd, Mumbai. 
Methanol Loba Chem. Pvt. Ltd, Mumbai.  
Sodium hydroxide S.D Fine Chem. Ltd., Mumbai. 
Potassium dihydrogen 
orthophosphate Loba Chem. Pvt. Ltd, Mumbai.  
Dulbecco’s Phosphate buffered 
saline ( DPBS) HiMedia Laboratories Pvt. Ltd. Mumbai.
Polysorbate-80 Loba Chem. Pvt. Ltd, Mumbai.  
Dialysis membrane HiMedia Laboratories Pvt. Ltd. Mumbai.
Dialysis Closure Clips HiMedia Laboratories Pvt. Ltd. Mumbai.
HPLC grade water Ranbaxy Fine Chemicals Ltd,     New Delhi. 
Deionised water PSG College of Pharmacy, Coimbatore. 
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EQUIPMENTS USED 
Equipments               Model/Company 
Digital Balance Shimadzu Electronic balance 
Magnetic stirrer Remi Electronics 
Freeze drier Labconco 
Cooling Centrifuge Eppendroff Centrifuge 
Vacuum filter Merck Ltd 
FT-IR spectrometer Shimadzu, 8400 S Model, 2006. 
HPLC Shimadzu, LC- 10 ATUP, 2005. 
Scanning Electron Microscopy JEOL, Model no JSM 6360 
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STANDARD GRAPH OF VALACYCLOVIR .HCL 
Procedure: 
 A Stock solution of Valacyclovir hydrochloride was prepared by 
dissolving 10 mg of pure drug in 10 ml of mobile phase at pH 6.5 to give 
1000 µg/ml. Then 1ml of stock solution was diluted to 10ml using mobile 
phase to produce 100µg/ml. From this working solution, dilutions were 
made to produce 100, 200, 300, 400, and 500 ng/ml.   
The UV detector was set at a wavelength of 271nm in RP-HPLC. 
An injection volume of 20 µL was used.        
Table .1 Standard graph of Valacyclovir. HCl 
S. No Concentration ng/ ml Peak area 
1. 0 0 
2. 100 131871 
3. 200 244829 
4. 300 365497 
5. 400 472283 
6. 500 587952 
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Fig. 9   Standard graph of Valacyclovir. HCl 
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PREPARATION OF BUFFER SOLUTIONS 
Preparation of Dulbecco’s phosphate buffered saline  
 Dulbecco’s phosphate buffered saline – (Bisodium 
phosphate/monobasic Potassium phosphate/Sodium chloride/ Potassium 
chloride (w/w/w/w = 1.15:2:8:0.2).  Place 0.96 gm of DPBS   in 100 ml 
standard flask add distilled water to dissolve and make up the volume. 
Preparation of 3N NaOH solution 
  Place 12gm of sodium hydroxide pellets in 100 ml standard flask 
add distilled water to dissolve and make up the volume. 
Preparation of 0.067 M KH2PO4 solution 
 Place 0.813 gm of potassium dihydrogen phosphate (KH2PO4) in 
100 ml standard flask add distilled water to dissolve and make up the 
volume. 
Preparation of mobile phase for standard graph in HPLC 
 The mobile phase prepared by mixing the Acetonitrile: Methanol: 
0.067 M KH2PO4 (27:20:53, V/V/V) in 1000 ml standard flask and adjusted 
to pH 6.5 with 3M sodium hydroxide and delivered at the flow rate of 
1Ml/min. (Ayhan Savaer et al., 2003). 
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Preparation of 0.2 m  potassium dihydrogen phosphate buffer 
 Place 62.5ml of 0.2M potassium dihydrogen phosphate in a 250ml 
volumetric flask, add the specified volume of 0.2M Sodium hydroxide and 
then add water to 250ml volumetric flask. 
Preparation of 0.2M potassium dihydrogen phosphate 
  Place 27.218gm of Potassium dihydrogen Phosphate pellets in 
1000 ml standard flask add distilled water to dissolve and make up the 
volume. 
Preparation of 0.2M sodium hydroxide 
 Place 8.4gm of Sodium hydroxide in 1000ml standard flask add 
distilled water to dissolve and make up the volume. 
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FORMULATION OF VALACYCLOVIR MMA-SPM NANOPARTICLES 
Preparation of Valacyclovir loaded Nanoparticles                                                              
               For 20ml 
Valacyclovir  - 20mg 
Ammonium persulfate 0.03% (w/v) - 6mg 
Methyl methacrylate 4.95% (w/v) - 0.99 ml 
Sulfopropyl methacrylate potassium   
Salt 0.05% (w/v) - 10mg 
D- Mannitol 4% (w/v) - 240mg   
Dulbecco’s phosphate buffer saline - q. s 
Polysorbate-80 0.01% (w/v) -  2mg 
 Valacyclovir Nanoparticles formulated by free radical polymerization 
method. In this method 10mg of sulfopropyl methacrylate (SPM) was 
mixed with 0.99ml of methyl methacrylate (MMA) in ultrapure deionized 
water. 6mg of Ammonium persulfate was added as an initiator, into the 
above solution under constant magnetic stirring at 78oC in 400 rpm over a 
period of 24 hrs to form methyl methacrylate sufopropyl methacrylate 
nanoparticle. MMA-SPM NP suspension was filtered through a filter paper 
pore size of 0.8 µm and lyophilized with 4% mannitol. The 20 mg of drug 
was added with pH adjusted with Dulbecco's phosphate buffer saline and 
allows stirr for 150 rpm at 37oC for 3 hrs. Then the 0.01% of polysorbate- 
80 was added to stabilize the formulation and it is lyophilized to form a 
powder of nanoparticles (Yung- Chin Kuo., (2005), F.Stieneker et 
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al., (1996), J. Kreuter et al., (1997). 
MECHANISM OF FORMATION OF NANOPARTICLES   
 
Free Radical Polymerization Method 
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 Fig. 10.     Procedure for preparation of Valacyclovir Nanoparticle 
 
 
 
400 rpm, 780 C, 24hrs  
4% Mannitol - 800 C, 30min, Freeze drying  
pH 2, 4, 6, 7.5, adjustment 
with DPBS
Add 20 mg VCV, 150 
rpm, 370C, 3 hrs. 
Add 0.01 % W/V 
Polysobate 80
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Table No. 2 
Preparation of Valacyclovir  MMA -SPM Nanoparticles 
S. 
No 
Formulation 
Code 
Formulation 
pH 
Drug  
Concentration 
in mg/ml 
Volume 
of MMA 
in ml 
Amount 
of SPM 
in mg  
1. NP1 2 20 0.99 10 
2. NP2 4 20 0.99 10 
3. NP3 6 20 0.99 10 
4. NP4 7.5 20 0.99 10 
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IN VITRO EVALUATION OF VCV MMA-SPM 
NANOPARTICLES 
 
METHODS 
1. Scanning electron microscopy (SEM) analysis 
2. Drug content and percentage drug loading  
3. Encapsulation efficiency  
4. In vitro release studies 
1. Scanning electron microscopy (SEM) analysis 
 The morphology of Valacyclovir MMA-SPM nanoparticles was 
examined by Scanning electron microscopy (SEM) JEOL JSM- 6360. The 
solid sample for SEM analysis was coated with a thin layer of platinum 
using the physical vapor deposition (PVD) process at 30mA current from 
the distance of 50 mm during 180 seconds. 
2. Determination Drug content and percentage drug loading  
To determine the drug content and percentage drug loading, 1.5 ml 
of Valacyclovir loaded MMA-SPM nanoparticle formulation (NP1, NP2, 
NP3 & NP4) was taken in eppondrof tube and centrifuged at 10,000 rpm at 
4°C for 3 hrs and the supernatant was analyzed in RP-HPLC at 271 nm. 
(Yung- Chin Kuo., 2005). 
100tan X
DrugofWeightTotal
tSupernainDrugDrugofWeightTotalLoadingDrug −=  
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3. Determination of encapsulation efficiency  
The encapsulation efficiency of formulation was determined by the 
followed equations. Encapsulation efficiency (E.E) was defined as the 
percentage of determined loading relative to the nominal (theoretical) 
loading (Yung-Chin Kuo et al 2005).     
100. X
volumeTotal
volumetotalinDrugofAmountThevolumeTotalEE −=  
4. In vitro drug release studies 
 In vitro release of Valacyclovir from formulations was measured by 
using a dialysis membrane 110 (12,000 da, HiMedia Lab. Pvt. Ltd, 
Mumbai). MMA-SPM nanoparticles were centrifuged in 10,000 rpm at 40 C 
for 3 hrs. The supernant was decanted the sediment suspension was 
preserved for in vitro release studies. 2 ml of the preserved suspension 
was filled in dialysis membrane and the packed membrane was immersed 
in 50 ml of Phosphate buffered saline (PBS) of pH 7.4 which was used as 
a medium at 37± 10C under constant stirring. At preset time intervals, 2ml 
of aliquots of the medium were withdrawn and the same volume was 
replaced by fresh medium to maintain the sink condition. The sample was 
analyzed by RP- HPLC.   (Masayuki yokoyama et al., (2005). 
Percentage of drug released (%) = (a/b) x 100 
a = Amount of VCV released, b = Amount of VCV entrapment 
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RESULTS AND DISCUSSION 
SEM ANALYSIS 
Fig.11 SEM picture of Valacyclovir loaded MMA-SPM Nanoparticles 
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DRUG CONTENT AND PERCENTAGE OF DRUG LOADING  
Table : 3  Drug content and drug loading efficiency of  
VCV MMA-SPM NP 
 
Formulation 
Code pH  of VCV 
MMA-SPM 
NP 
formulation
Peak 
area 
Concentration 
in ng/ml 
Drug 
Content  in   
1.5 ml of 
VCV MMA-
SPM NP 
formulation  
(ng) 
Percentage 
of drug 
loading 
efficiency 
(%) 
NP1 pH 2 58265 88.2 1.42 71 
NP2 pH 4 49532 75.1 1.51 75.5 
NP3 pH 6 43443 65.9 1.57 78.5 
NP4 pH 7.5 40911 62.1 1.59 79.5 
  
Fig.  12 Drug loading chromatogram of RP-HPLC  VCV MMA-SPM NP 
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Fig.  13.  Drug content analysis 
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Fig. 14. Percentage of drug loading efficiency 
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IN VITRO RELEASE STUDIES 
Table: 4   In vitro drug release profile of Valacyclovir Nanoparticles 
(NP4) by RP-HPLC 
 
Time in Hrs Peak area Percentage drug release 
1 98046±60.34 17±0.91 
2 102280±99.17 18±0.86 
3 120255±78.57 21±0.72 
4 144512±97.62 26±0.78 
5 165743±88.56 29±0.74 
6 182716±82.32. 32±0.58 
7 198974±64.32 35±0.59 
8 228918±75.61 41±0.43 
9 234876±90.52 42±0.41 
10 249452±102.3 44±0.39 
11 264029±96.68 47±0.35 
12 287254±85.26 51±0.32 
13 297143±88.01 53±0.30 
14 312784±42.56 56±0.28 
15 326248±77.80 58±0.26 
16 335931±34.48 60±0.24 
17 349783±49.54 63±0.27 
18 356551±59.41 64±0.23 
19 368498±67.67 66±0.20 
20 376629±96.93 67±1.20 
21 383248±99.01 69±1.43 
22 396522±84.12 71±1.46 
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23 404893±87.65 73±1.47 
24 417821±79.43 75±1.49 
 
Fig. 15 In vitro drug release profile of Valacyclovir Nanoparticles at 
different time intervals 
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1. Particle size and surface analysis using SEM 
 Scanning electron microscopy reveals that all prepared 
nanoparticles had a homogeneous solid matrix structure, with no evidence 
of crystals on the surface (Fig.11). The Valacyclovir loaded nanoparticles 
prepared by free radical polymerization method enables us to get 
spherical, discrete spheres with a size ranging from 80 t0 110nm.  
2. Drug content and percentage drug loading  
 The results of drug content and percentage drug loading was 
shown in table. The results were suggesting that the nanoparticles loaded 
in pH 7.5 was found to have high drug content while compared to other pH 
conditions. The loading efficiency is found to be pH dependent which is 
directly proportional. The drug content of formulations NP1, NP2, NP3 and 
NP4 were found to be 1.42, 1.51, 1.57 and 1.59 respectively. The 
percentage of drug loading was found to be 71%, 75.5%, 78.5% and 
79.5%.  
3. Percentage Encapsulation efficiency 
 The results of encapsulation efficiency was shown in table. The 
encapsulation efficiency of formulations NP1, NP2, NP3 and NP4 was 
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found to be 29%, 24.5%, 21.5% and 20.5% respectively. It is evident that 
the pH is indirectly proportional to the percentage encapsulation efficiency. 
 
4. In vitro release studies 
 The MMA-SPM nanoparticles loaded with Valacyclovir in pH 7.4 
(formulation NP4) was found to have high drug content and high 
percentage loading which found to be the best formulation compared to 
other formulation. So, NP4 was selected for the in vitro release studies.  
The in vitro drug release profile was shown in table & fig. the in vitro 
release study was carried out in pH 7.4. The results suggest that the 
release was found to be sustained for more than 24 hrs. Around 75% of 
drug was released at the end of 24 hrs. the outcome of release profile 
indicating that the MMA-SPM nanoparticles loaded with Valacyclovir  can 
be used as controlled release formulation. 
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SUMMARY AND CONCLUSION 
 Herpes simplex virus (HSV) is a human DNA virus with two species, 
HSV-1 and HSV2,  that causes a variety of disease manifestations. The 
major public health importance of HSV2 lies in its potential role as a 
cofactor for HIV transmission. Valacyclovir is an oral antiviral drug which 
included in the antiretroviral therapy prolongs survival in HIV seropositive 
individuals. The Valacyclovir is having low bioavailability profile with 
toxicity and adverse reactions in high dose.  
 The present work was proposed to prepare MMA-SPM 
nanoparticles loaded with Valacyclovir to achieve better bioavailability with 
lowest possible dose. From the plethora of literatures it was found that 
MMA-SPM NPs are suitable carrier for hydrophilic or even charged 
molecules (Langer et al., 1997). The MMA-SPM nanoparticles were 
prepared and the drug was loaded in different pH environment. 
 The prepared NPs are evaluated for different parameter. The 
particle size and surface morphology results revealed that the 
nanoparticles are in the size range of 80 – 110 nm. Which may be useful 
for targeting the Nps to macrophages or monocytes. The in vitro release 
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suggests that the Nanoparticles shows a better controlled release profile  
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for more than 24 hrs. The frequency of the doses can be reduced due to 
the controlled release nature. The NPs is targeted delivery devices which 
will be useful to reduce the dose level of Valacylclovir.  
 To conclude, the prepared nanoparticles may be used to achieve 
the better bioavailability profile with targeting to the macrophages.  
The in vivo studies may be carried out to optimize the therapeutic 
response of the prepared nanoparticles.       
  
 
 
 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
BIBLIOGRAPHY 
 
Anne Engelbrecht Thomsen., Michael Soberg Christensen., Morten Aavad 
Bagger., Bente Steffansen., 2004. Acyclovir prodrug for the 
intestinal di/tri-peptide transporter PEPT1: comparison of in vivo 
bioavailability in rats and transport in Caco-2 cells. Eur. J. Pharm. 
Sci. 23, 319–325. 
Avinash Budhian., Steven, J., Siegel., Karen, I., Winey 2005. Production of 
haloperidol-loaded PLGA nanoparticles for extended controlled 
drug release of haloperidol. Int. J. Pharm.344, 33-43.22(7), 773-
785.   
Ayhan Savaer., Cansel, K., Ozkan., Yalcn Ozkan., Bengi Uslu., Sibel 
Ozkan., 2003. Development and Validation an RP-HPLC Method 
for the Determination of Valacyclovir in Tablets and Human Serum 
and its Application to Drug Dissolution Studies. J. Liq. Chrom. Tech. 
26, 1755-1767. 
Dogan-Topal,B.,  Uslu,B.,  Ozkan,D.A., 2007. Development and Validation 
of an RP-HPLC Method for Determination of Valganciclovir in 
Human Serum and Tablets. Chromatographia Supplement. 66, 97–
101. 
Dohner and Socdeik., 2005. Role of nanotechnology in developing antiviral 
agents. A Review. Asian J. Pharm.10-20.   
E,Ga de Jalo na., M,J, Blanco-Prıetoa., P, Ygartuaa., S, Santoyob., 2003. 
Increased efficacy of acyclovir-loaded microparticles against herpes 
simplex virus type 1 in cell culture. Eur.J. Pharm. and Biopharm. 56, 
183–187. 
Erion., Norin., Berges., 2005. Antiviral therapeutic technologies in markets 
and companies, Asian J. Pharm. 43-50. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
Fakhrul Ahsan., Isabel, P., Rivas., Mansoor, A., Khan., Ana, I., Torres 
Suarez., 2002. Targeting to macrophages: role of physicochemical 
properties of particulate carriers—liposomes and microspheres on 
the phagocytosis by macrophages. J. Controll. Release. 79, 29–40. 
Fakhrul Ahsan., Isabel, P., Rivas., Mansoor, A., Khan., Ana, I., Torres 
Suarez., 2002. Targeting to macrophages: role of physicochemical 
properties of particulate carriers—liposomes and microspheres—on 
the phagocytosis by macrophages. J.Controll. Release. 79, 29–40. 
Fu Chen., Zhi-Rong Zhang., Yuan Huang., 2007. Evalation and 
modification of N-trimethyl chitosan chloridenanoparticles as protein 
carriers. Int. J. pharm. 336, 166-173. 
Genevieve Gaucher., Monia poreba., Francois Ravenelle., Jean-Chistophe 
leroux.,1999. Poly (N-Vinyl-Pyrrolidine ) – Block-Poly(D,L- Lactide) 
as Polymeric Emulsifier for the preparation of Biodegradable 
Nanoparticles. J.Pharm. Sci. 96, 7. 
Gladys E Granero., Gordon L Amidon., 2006. Stability of Valacyclovir: 
Implications for its oral bioavailability. Int. J. Pharma. 317, 14–18. 
Hagen von Briesen., Andreas R., Bender., Jo Rg Kreuter., Ian B, Duncan., 
Helga Ru Bsamen-Waigmann., 1996. Efficiency of Nanoparticles as 
a Carrier System for Antiviral Agents in Human   Immunodeficiency 
Virus-Infected Human Monocytes/ Macrophages In Vitro, Antim. 
Agents. Chemoth. 137-147 
Hideki Murakami., Masao Kobayoshi., hirfumi takeuchi., Yoshiaki 
kawashima., 1999. Preparation of poly (DL-lactide-co-glycolide) 
nanoparticles by modified spontaneous emulsification solvent 
diffusion method. Int.J. pharm 187, 143-152. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
Hidenori Otsuka., Yukio Nagasaki., Kazunori Katoka., 2003. PEGylated 
nanoparticles for biological and pharmaceutical applications. 
Advanced drug delivery rivews 5, 403-419. 
Huli-li Ma., Xian-rong Qi., Yoshie Maitani., Tsuneji Nagai., 2007. 
Preparation and charecterization of superamagnetic iron oxide 
nanoparticles stabilized by alginate. Int.J. pharm 344, 33-43.  
Hyun-Jeon., young jeong., Jae woon Nah., 2000. Effect of solvent on the 
preparation of surfactant-free poly (DL-lactide-co-glycolide 
nanoparticles and norfloxacin release characteristics. Int. J. pharm. 
207, 99-108. 
Ivan Sondi., olavi Siiman., Egon matijevic., 2004, Synthesis of CdSe 
nanoparticles in the presence of aminodextran as stabilising and 
capping agent. J. colloid and interface sci. 275,503-507. 
Jia K, Li., Nuo Wang., Xue S, Wu., 1997. A novel biodegradable system 
based on Gelatin Nanoparticles and poly lactic-co-glycolic acid) 
Micrspheres for Protein and Peptide Drug Delivery.  
J. Pharm. sci. 86, 8. 
Jie Liu., Wen Hu., Huabing Chen., 2007. Isotretinoin-loaded solid lipid 
nanoparticles with skin targeting for topical delivery. Int. J. Pharm 
328, 191-195. 
John G, Eley., Priyanka Mathew., 2006. Preparation and release 
characteristics of insulin and insulin growth factor-one from polymer 
nanoparticles. J. micro 24(3), 225-234.  
Juan, M. Irache., Laurance Bergougoux., Isabel ezepeleta., 1995. 
Optimization and in vitro stability of legumin nanoparticles obtained 
by a coacervation method. Int. J. pharm. 126, 103-109. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
K,Yoncheva., Guembe,I., Irache,J,M., 2007. Evaluation of bioadhesive 
potential and intestinal transport of pegylated poly(anhydride) 
nanoparticles. Int. J. pharm. 334, 156-165. 
Karl Beutner., 1995. Valacyclovir a review of its antiviral activity, 
pharmacokinetic properties, and clinical efficacy. Antiviral 
Research, 28, 281- 290. 
Kunn Hadinoto., Kewu Zhu., Reginald B,H., Tan., 2007. Drug release 
study of hollow nanoparticulated aggregates carrier particles for 
pulmonary delivery. Int.J. Pharm 344, 195-206 
Kunn Hadinoto., Ponpan Phanapavudhikul., Reginald B,H, Tan., 2007. Dry 
powder aerosol delivery of large hollow nanoparticulated 
aggregates as prospective carriers of nanoparticulated drugs: 
Effects of phospholipids. Int. J. Pharm.333, 187-198. 
Leonid Kagan., Ammon Hoffman., 2008. Selection of drug candidates for 
gastroretentive dosage forms: Pharmacokinetics following 
continuous intragastric mode of administration in a rat model.  
Eur. J. Pharm. and Biopharm. 69, 238–246. 
Marta Merodio., Amaia Arnedo, M., Jesus Renedo., Juan Irache., 2001. 
Ganciclovir-loaded albumin nanoparticles: characterization and in 
vitro release properties. Eur. J. Pharma. Sci. 12, 251–259. 
Masayuki yokoyama., Praneet opanasopit., Masato watanabe., Kumi 
kawano., Yoshie Maitani., Teruo okano., 2005. Influence of serum 
and albumins from different species on Stability of Camptothecin 
loaded micelles. J.Controll. Release. 104, 313- 321. 
Molpeceres, J., Chacón, M., Guzmán, M., Berges, L., Aberturas, M, R., 
1999. polycaprolactone nanoparticle formulation of cyclosporin-A 
improves the prediction of area under the curve using a limited 
sampling strategy. Int. J. Pharm., 187(1), 101-113. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
Neeraj Kumar., Majeti, N,V., Ravikumar, A,J., Domb., 2001. Biodegradable 
block copolymers. Advanced Drug Delivery. 53, 23–44. 
Nevine Rizkalla., Charlotte Range., 2006. Effect of various formulation 
parameters on the properties of polymeric nanoparticles prepared 
by multiple emulsion method.  J. Microencapsu. 23(1), 39-57. 
Philippe legrand., Sylviane Leiieur., Chistine Vauhtier., 2007. Influence of 
polymer behavier in organic solution on the production of 
polylactide nanoparticles by nanoprecipitation. Int. J. Pharm. 
344, 33-43.                            
Pilli N,Rao., Raja Rajeswari,K., Jayathirtha Rao,V., Seshagiri Rao., 2006. 
RP-HPLC Estimation of Valacyclovir in Tablets. Asian J. Chem. 18, 
2552-2556. 
Pitt, C, G., Chasin,M., Langer, R., 1990. Poly-ε-caprolactone and its 
copolymers, in Biodegradable Polymers as Drug Delivery Systems, 
Editor., Marcel Dekker Inc: New York, 71-119. 
Raja Rajeswari,K., Nageswararao,P., Sankar,G,G., Rao, A,L., Raju, A,L.,  
2006. Estimation of Valacyclovir in Tablets and Human Serum by 
RP-HPLC Method. Asian J. Chem., 18, 2515-2518. 
Rajinder, K., Bhardwaj., Dea Herrera-Ruiz., Nesreen Eltoukhy., Maha 
Saad., Gregory T, Knipp., 2006. The functional evaluation of human 
peptide/histidine transporter 1 (hPHT1) in transiently  
transfected COS-7 cells. Eur. J. Pharm. and Biopharm. 27,  
533–542.  
Rubiana M., Mainardes., Raul C, Evangelista., 2005. PLGA nanoparticles 
containing praziquantel: effect of formulation variables on size 
distribution. Int.J. pharm. 290, 137-144. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
S,R, Schaffazick., A,r, pohlmann., C,A,S,De Cordova., S,S Guterres., 
Protective properties of melatonin-loaded nanoparticles against lipid 
peroxidation. Int. J. pharm 289, 209-213.  
Sanghoon ko., Sundaram Gunasekaran., 2006. Preparation of sub-100-
nm β-lactoglobulin (BLG) nanoparticles. J. Microencapsu, 23(8), 
887-898. 
Sheik Hasan,A., Socha,A., Lamprecht,A., Ghazouani,E.I., Sapin,A., 
Hoffman,M., Maincent,P., Ubrich,N., 2007. Effect of the 
microencapsulation of nanoparticles on the reduction of burst 
release. Int.J. pharm 344, 53-61. 
Singh, M., Briones., Ott,G., OHagan,O., 2000. Cationic microparticles: A 
potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. 
U.S.A. 97, 811-816. 
Srinu Babu,G., Sarat Babu,I., Kiran Kumar,N., Yugandhar,N,M., Raju,A.I., 
2007. Development of HPLC method for the Estimation of 
Valacyclovir in Tablet Dosage Form. Asian J. Chem., 19, 1639-
1641.  
Sspassi,S., Goodwin., Darke,A,F., Holland,S., Leonard,G., Martini,L., 
Lawrance,M.J., 2006. Effect of polymer molecular weight on the 
production of drug nanoparticles. J. Pharm. Sci. 96,10. 
Suresh Katragadda., Ritesh Jain., Deep Kwatra., Sudharshan Hariharan., 
Ashim, K., Mitra., 2008. Pharmacokinetics of amino acid ester 
prodrugs of acyclovir after oral administration: Interaction with the 
transporters on Caco-2 cell. Int. J. Pharm. 362, 93–101. 
 
 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
U,Bilati., E,Allemann., E,Doelker., 2004. Poly (D,L-Lactide-co-glycolide) 
protein-loaded nanoparticles prepared by the double emulsion 
method- processing and issues for enhanced entrapment efficiency. 
J. microencapsu. 2292), 203-214. 
Vijayakumar., Gilbert, S,B., 2001. Modern Pharmaceutics, 3rd edition, 
 Informa HealthCare. 73, 613. 
Volhard jenning., Karsten madder., Sven, H., Gohla., 2000. Solid lipid 
nanoparticles (SLNTM) based on binary mixtures of liqid and solid 
lipids: a H-NMR study. Int.J. pharm 205, 15- 21. 
Waree tiyaboonchai., 2003. Chitosen Nanoparticles : A Promising 
systemfor drug delivery. Naresuan University Journal 11(3), 51-66. 
Waree Tiyaboonchai., Nanteetip., 2007. Formulation and characterization 
of amphotericin B-chitosan-dextran sulfate nanoparticles.  
Int. J. pharm, 329, 142-149. 
Yang,J., Lee,H., Hyung,W., Park,S.B., Haam,S., 2005. Magnetic PECA 
nanoparticles as drug carriers for targeteddelivery: synthesis and 
release characterstics. J. microencapsulation 23(2), 203 -212. 
Yiguang Jin., Li Tong., Ping Ai., Miao Li., Xinpu Hou., 2006. Self-
assembled drug delivery systems 1. Properties and in vitro  / in vivo 
behavior of Acyclovir self-assembled nanoparticles (SAN). Int. J. 
Pharm. 309, 199–207. 
Yongli Zheng., Yan wu., Changchun wang., Shoukuan., Xizhong shen., 
2005.Preparation, characterization and Drug release In Vitro 
chitosan-Glycyrrhetic Acid nanoparticles. J. Pharma. 95, 1. 
Yulu Wang., Rajesh, M., Dave., Robert Pfeffer., 2004. Polymer coating / 
encapsulation of nanoparticles using a supercritical anti-solvent 
process. J. of Supercritical Fluids 28, 85-99. 
Bibliography 
HSV2 inhibition with HIV Suppressing Nanoparticles For 
Targeted Drug Delivery Of Macrophages/ Monocytes 
 
Yung-Chih Kuo., 2005. Loading efficiency of Stavudine on 
polybutylcyanoacrylate and methylmethacrylate-sulfopropyl-
methacrylate copolymer nanoparticles. Int. J. Pharm. 290, 161–172. 
Yung-Chih Kuo., Fu-Lung Su., 2007. Transport of Stavudine,  
Delavirdine, and Saquinavir across the blood–brain  
barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropyl-
methacrylate, and solid lipid nanoparticles. Int. J. Pharma. 340, 
143–152. 
ZHANG Zhi-Rong., HE Qin., 1999. Study on liver targeting and 
hepatocytes permeable Valaciclovir polybutylcyanoacrylate 
nanoparticles. World J. Gastroen. 5(4), 330-333. 
